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Abstract 
Genetic modification of dendritic cells with plasmid DNA is plagued with low 
transfection efficiencies because DNA taken up by non-dividing dendritic cells rarely 
reaches the nucleus. But this difficulty can be overcome by the use of messenger RNA 
(mRNA), which exerts its biological function in the cytoplasm and obviates the need to 
enter the nucleus. Since pioneering work of Boczkwoski et al., 1 the ex-vivo application of 
mRNA-transfected dendritic cells as a vaccine has been evaluated in numerous phase I 
trials worldwide2, 3 and is still currently being actively optimized in clinical trials.  
However, a major disadvantage of using mRNA-transfected DCs as a vaccine is 
that it requires patients to undergo at least one 4-hour leukapheresis procedure, followed 
by separation of the peripheral blood mononuclear cells (PBMCs), from which 
monocytes are isolated and cultured for a week in a defined medium with cytokines. The 
resulting DCs are matured after being loaded with mRNA and frozen for storage. 
Aliquots are subsequently thawed prior to administration to patients. This process of 
harvesting, culturing and loading DCs is more time- and resource-intensive than 
Provenge, the first FDA approved cell based tumor vaccine in 2011.4 Recent evidence 
has confirmed a lack of broad translation of Provenge due to complexity and cost of 
treatment. This predicates a similar fate for mRNA-transfected dendritic cell vaccine 
going forward.5, 6  
This thesis presents alternative delivery strategies for mRNA mediated tumor 
vaccination. Through the application of synthetic and natural biomaterials, this thesis 
demonstrates two viable approaches that reduce or eliminate the need for extensive 
manipulation and cell culture. 
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The first approach is the direct in vivo delivery of mRNA encapsulated in 
nanoparticles for tumor vaccination. A selected number of synthetic gene carriers that 
have been shown to be effective for other applications are formulated with mRNA into 
nanoparticles and evaluated for their ability to transfect primary DCs. The best 
performing formulation is observed to transfect primary murine and human monocyte 
derived dendritic cells with an efficiency of 60% and 50% (based on %GFP+ cells) 
respectively. The in vivo transfection efficiency and expression kinetics of this 
formulation is subsequently evaluated and compared with naked mRNA via various 
routes of delivery. Following this, a proof-of-concept study is presented for a non-
invasive method of mRNA tumor vaccination using intranasally administered mRNA 
encapsulated in nanoparticles. Results show that intranasally administered mRNA 
induces tumor immunity only if it is encapsulated in nanoparticles. And anti-tumor 
immunity is observed in mice intranasally immunized under both prophylactic as well as 
therapeutic models.  
The second approach evaluates whole blood cells as alternative cell based mRNA 
carriers. A method is developed to encapsulate intact and functional mRNA in murine 
whole blood cells. Whole blood cells loaded with mRNA not only include erythrocytes but 
also T cells (CD3+), monocytes (CD11b), antigen presenting cells (MHC class II) as well 
as plasmacytoid DCs (CD45R-B220). Mice immunized with mRNA-loaded whole blood 
cells (intravenously) develop both humoral and cellular antigen-specific immune 
responses, and demonstrate delayed tumor onset and progression in a melanoma 
therapeutic immunization model (using tyrosinase related protein -2, TRP-2, as an 
antigen). Importantly, the therapeutic efficacy of mRNA-loaded whole blood cell vaccine 
vi 
 
formulation is found to be comparable to mRNA-transfected dendritic cell vaccine 
(administered intraperitoneally). 
In conclusion, this thesis presents new methods to the delivery of mRNA tumor 
vaccines that reduce or eliminates the need for extensive cell manipulation and culture. 
Results presented in this thesis reveal viable research directions towards the 
development and optimization of mRNA delivery technologies that will address the 
problem of broad translation of mRNA tumor vaccines in the clinics.  
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transfected with an unrelated RNA. Later studies show that DCs transfected with mRNA 
using electroporation are more effective T cell stimulators than DCs passively pulsed 
with mRNA (delivered via DOTAP liposomes).8  As shown on Table 1, there is 
accumulating clinical evidence that vaccines consisting of autologous DCs transfected 
with mRNA encoding tumor associated antigens (via electroporation) are safe, well 
tolerated and capable of inducing tumor antigen specific immune response. 2, 3 Although 
objective tumor regression was not always observed, these clinical trials affirm the 
concept of mRNA-DC tumor vaccination and opens up opportunities for further 
optimization. 
Several optimization approaches to mRNA-DC vaccine have been reported. The first 
strategy employed is the use of a cytokine cocktail to induce full DC maturation. Fully 
matured DCs secretes IL-12 (both subunits p40 and p70) that support T cell function, 21 
express co-stimulatory molecules such as CD70/80/86,22 chemokine markers such as 
CCL19 and CCL21 that increases it migratory capacity towards the lymph node,23 as well 
as additional pro-inflammatory cytokines.21  To date a few maturation cocktails have 
been established: namely the IL-6/IL-1β/TNF-α/PGE2 combination, 3 the LPS/IFN- 
combination, 20 or KLH/TNF-α/PGE2 combination. 3  
The second strategy is co-electroporation of adjuvant molecules alongside antigen 
encoding mRNA. The rationale of this strategy is to modulate DC function leading to 
enhanced DC antigen presentation capacities. For example, the co-electroporation of 
TriMix mRNA (CD70/ constitutiveTLR4/ CD40L) facilitates the full DC maturation without 
the need for overnight culture of electroporation DCs. 13 DCs can be used for vaccination 
immediately after their recovery from electroporation procedure. In another approach, 
DCs were separately loaded with mRNA encoding for anti-GITR (glucocorticoid-induced 
tumor necrosis factor receptor) antibody. These DCs were mixed with DCs loaded with 
4 
 
mRNA encoding tumor antigen and immunized into mice. GITR, a member of the tumor 
necrosis factor receptor superfamily, is constitutively expressed on Tregs but it is also 
expressed at low levels on multiple immune cells, including T cells, natural killer cells 
and B cells in which it is up-regulated on activation. 24 Several studies have shown that 
anti-GITR, alone or as an adjunct to active immunization, increases the ability to break 
immune tolerance. 25-27 Co-delivering DCs transfected with mRNA that encodes for GITR 
and tumor antigen increases therapeutic efficacy through the modulation of effector T 
cell suppression, although the exact mechanism has yet been delineated. 10 A third co-
delivery approach is to co-electroporation siRNA that targets immunoproteasomes in 
DCs. Many cancers, including melanoma, exclusively express constitutive proteasomes 
and are unable to express immunoproteasomes. In contrast, mature DCs used for 
immunotherapy exclusively express immunoproteasomes. Since proteasomes generate 
peptides presented by HLA class I molecules, knocking down immunoproteasomes (with 
siRNA) skews peptide production towards constitutive proteasome. The idea is to 
increase the quality of antigen presentation leading to enhanced anti-tumor immunity. 
This approach has been shown to be effective in patients as circulating melanoma cell 
levels fell, and T cell lytic activity against autologous melanoma was induced. Of two 
subjects with active disease, one had a partial clinical response, while the other, who 
exhibited diffuse dermal and soft tissue metastases, had a complete response. 15 
The third optimization strategy is the determination of the route of delivery that will lead 
to highest lymph node accumulation, immune response or clinical outcome. mRNA 
transfected DCs need to reach the lymph nodes to induce a potent immune response. 
Different routes of vaccination such as intradermal (ID), subcutaneous (SC), intranodal 
(IN) as well as intravenous (IV) administrations have been tested during clinical trials. 
Labelling of DCs with Indium111 and subsequent imaging of their migration has 
5 
 
demonstrated that SC administered DCs rarely reach lymph nodes. Similarly, IV injected 
DCs does not result in their accumulation in lymph nodes but in an initial accumulation in 
the lungs and subsequent redistribution to the liver, spleen and bone marrow. 28 In 
contrast, about 4% of ID administered DCs are recovered from lymph nodes. 29 In 
addition, DCs were shown to co-localize with T cells efficiently in draining lymph nodes 
after intranodal administration. 30 Importantly, in a study that compared intranodal and 
intradermal administration of ex vivo modified DCs in patients with advanced melanoma 
found that despite a higher number of DCs in lymph nodes after intranodal 
administration, intradermal injection proved to be superior in inducing functional tumor 
antigen-specific T cells. 31 
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Figure 1. mRNA dendritic cell vaccine preparation process in mouse and humans 
7 
    
Table 1. Clinical efficacy of ex-vivo application of mRNA transfected DCs for tumor immunotherapy 
 
Abbrev: i.d., intradermal; i.n., intranodal; i.v., intravenous; KLH, keyhole limpet hemocyanin; DTH, delayed type hypersensitivity; hTERT , 
human telomerase reverse transcriptase; PSA, prostate specific antigen; CEA , carcinoembryonic antigen; SD, stable disease; CR, 
complete response; PD, progressive disease; LAM P-1, lysosome-associated membrane protein-1; PGE2, prostaglandin E2; IL, 
interleukin; TN F, tumor necrosis factor; WT-1, Wilms’ tumor-1; TAA , tumor-associated antigen; HLA, human leukocyte antigen; IFN, 
interferon; TriMix mRNA , a mix of 3 mRNA molecules encoding CD70, CD40L and a constitutive active form of toll-like receptor 4 
(caTLR4);  
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research in nanomedicine. There is also growing interest in gene delivery groups who 
are venturing into the mRNA arena, as well as mRNA vaccinologists who are 
venturing out in search for effective ways to deliver mRNA to antigen presenting cells 
in vivo. It would seem that after almost two decade of advances made in nucleic acid 
delivery systems of RNAi and DNA that we would have solved the problem of mRNA 
delivery to dendritic cells, but we have not, at least not yet. Nevertheless, a good 
understanding of gene delivery barriers has been achieved in the gene delivery field 
and many tools have also been developed to address these delivery barriers. In 
addition, the immunological properties of mRNA, signalling pathways through pattern-
recognition receptors (e.g. TLR, RLRs) and their implications on immune responses 
have also been characterized in recent years. Hence, we are at an appropriate 
juncture in time where knowledge in engineering sciences can accelerate the clinical 
translation of mRNA and help fulfil its true potential.  
In this chapter we will first discuss whether mRNA is amenable for engineering 
manipulation. We will then draw on knowledge of gene delivery and mRNA 
immunotherapy to put together a frame work for mRNA nanoparticle tumour 
vaccination. This frame work is a set of delivery and biological barriers highlighting 
rate limiting steps to antigen presentation mediated by mRNA nanoparticle vaccine: 
gene delivery (extracellular and intracellular), immune activation and MHC 
presentation (Figure 2). We will describe and discuss these barriers within the 
context of genetic immunization with examples from published studies on mRNA 
nanoparticle tumour vaccination and DC transfection. Studies evaluating the optimal 
application of mRNA nanoparticle vaccination have often been performed in niche 
10 
 
areas (either delivery focused or immunology focused). It is also the aim of this 
review to put these studies together into an overall picture to help identify bottlenecks 
to mRNA nanoparticle mediated immunization.  
11 
  
 
Figure 2. Frame work for mRNA nanoparticle mediated tumor vaccination. 
Proposed frame work for mRNA nanoparticle mediated tumour vaccination. A combination of 
three overlapping processes determines immune response: gene delivery, immune activation, 
and major histocompatibility complex (MHC) presentation. In this framework, nanoparticles 
administered into the body have to overcome extracellular barriers from the site of 
administration to antigen presenting cells. After cell uptake, nanoparticles have to escape the 
endosome and mRNA has to unpack from the gene carrier and enter the protein translation 
pathway. At the same time, through pattern recognition receptors, mRNA nanoparticle needs 
to mediate immune activation (via TLR3,7/RIG-I,MDA5) so that cytokines are secreted for 
ensuing adaptive immune responses. Protein translated from delivered mRNA molecule 
needs to enter both the MHC I (via proteasome) and II (via lysosome) processing pathways so 
that antigen peptides can be presented on both MHC I and II molecules.
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modified nucleotides are also building blocks of structural RNAs such as ribosomes, 
which are non-immunogenic and relatively resistant to degradation.  
 
Figure 3. Solution stability of mRNA. 
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(a) Ctrl: control, V: mRNA vortexed at max speed for 9 minutes and incubated at 4oC overnight, 
S: mRNA sonicated (bath-type) for 3 minutes.  
(b) Agarose gel electrophoresis of mRNA diluted into various buffer (200g/ml) and incubated at 
room temperature for 6 days. G: 5% glucose (unbuffered solution), H: 100mM Hepes, N: 
100mM sodium acetate, Ctrl: control mRNA stored at -20oC, P: PBS, R: Ringer’s lactate, B: 
0.75% sodium bicarbonate.  
(c) Degradation profiles of mRNA analyzed on agarose gel (quantified with densitometry 
analysis). mRNA is incubated at 37oC in various buffers (symbols) or at room temperature in 
sodium bicarbonate (line)  
(d) Agarose gel electrophoresis analysis on structural integrity of mRNA incubated at 37oC in 
various buffers over 6 days (only day 2,4,6 are shown). 
(e) Agarose gel electrophoresis of mRNA stored in water (RNA-W) or trehalose (RNA-T) over 
time. “F” indicates freeze-dried RNA.49  
(f) Agarose gel electrophoresis analysis of structural integrity of DNA encapsulated in PEG cross-
linked hydrogels  
(g) Agarose gel electrophoresis analysis of structural integrity of DNA encapsulated in UV-cross-
linked hydrogels.50  
(h) Bioactivity of DNA released from hydrogels cross-linked using different UV intensity.51  
(a) – (d) are unpublished data. (e)-(h) are reproduced with permission.49,50,51 
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Enhanced biological stability and performance of mRNA in vivo attract the attention of 
biomedical engineers because of the opportunities to incorporate mRNA into medical 
devices for therapeutic applications. Being a “late bloomer”, many devices that have 
been built for DNA have not been well developed for mRNA, such as nano-/micro- 
particles, transcutaneous microneedles,52, 53 hydrogels50, 51, 54 and other 
macroformulations55. The question then becomes whether mRNA can be physically 
and/or chemically stable enough to be manipulated under fabrication conditions. 
Through various publications from biomedical engineering groups, it can be certain that 
mRNA can withstand conditions associated with nanoparticle formulation. As shown in 
Figure 3a (unpublished data), mRNA can withstand significant vortex-induced shear 
stress, but rapidly degrades upon sonication. Freeze dried mRNA and mRNA stored in 
trehalose at 4oC can remain stable for up to 10 months (Figure 3b).49 The former is a 
feasible method to obtain highly concentrated mRNA dissolved in the desired buffer 
compared to column recovery (e.g. RNeasy cleanup kit). Solution stability of naked 
mRNA is a key piece of information currently missing in the context of the development 
of controlled release devices such as hydrogels. Notwithstanding commercially available 
RNA storage solutions of proprietary nature, to develop encapsulation technologies, 
biomedical engineers need to know the physical stability of in vitro transcribed mRNA in 
common defined buffers. At present, this information can only be found for pure water 
and trehalose (Figure 3b).49 In fact, mRNA can be highly stable at room temperature but 
degrades with varying degrees at physiological temperature (Figure 3c, 3d and 3e). 
Degradation is a result of chemical hydrolysis of the phosphodiester bond of mRNA 
backbone caused by nucleophillic attack from hydroxide ions or 2’-OH group present in 
the ribose sugar residues of mRNA itself. At 37oC, mRNA remains relatively stable in 
16 
 
Hepes, PBS and sodium acetate, degrades gradually over time in Ringer’s lactate and 
5% glucose (non-buffered) solution, but degrades rapidly in sodium bicarbonate (Figure 
3e). Using densitometry quantification (Image J), degradation profiles in different buffers 
at 37oC are quantified and plotted on Figure 2c. At room temperature, mRNA remains 
stable in all buffers except sodium bicarbonate (Figure 3d). At 4oC, mRNA is highly 
stable in all buffers including bicarbonate (data not shown) and is consistent with 
published data shown in Figure 3b. 
The solution stability of mRNA is indeed lower compared to plasmid DNA. Plasmid 
DNA’s solution stability has been demonstrated in hydrogels. Agarose gel 
electrophoresis shows that DNA recovered from PEG cross-linked hydrogels remain 
intact after being left at 37oC for up to 10 days (Figure 3f)50 and 14 days (Figure 3g)51, 
respectively. The proportion of DNA in relaxed conformation increased while the 
supercoiled conformation decreased over time.50, 51 This is consistent with stability 
studies conducted in our lab (data not shown). While UV can inactivate plasmid DNA in a 
dose dependent manner, changes from coiled to relax conformation did not significantly 
affect the bioactivity of plasmid DNA released from hydrogels throughout the 14 day 
duration of the study (Figure 3h).51 
In summary, mRNA is highly shear resistant and hence it can be mixed more efficiently 
with gene carriers during formulation to form higher quality particles. In addition, solution 
stability of mRNA is not a limiting factor in the fabrication of mRNA based biomedical 
devices because it is compatible with commonly used buffers and can remain stable at 
room temperature during the fabrication process. However, it will may limited by 
chemical hydrolysis at physiological temperature and may not be suitable for long term 
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impediments to efficient transport of nanoparticles from the point of administration to the 
antigen presenting cells. To achieve the latter, nanoparticles have to overcome 
intracellular barriers defined as the ability to escape the endosomes and efficiently 
released from the gene carrier (discussed in the next section). The route of 
administration, no doubt, determines the magnitude of extracellular barrier. As this is a 
diverse yet well reviewed topic,56-58 we will focus our discussion on extracellular barriers 
of systemic, subcutaneous and intranasal route of administration, highlighting delivery 
barriers and ideal nanoparticle properties. 
1.2.3.2 Systemic Administration 
In systemic delivery, colloidal stability of mRNA nanoparticles is critical to ensure 
efficient transport through the blood stream to the target organs, preferably the spleen. 
Colloidal instability can be caused by particle aggregation when cationic gene carrier 
itself bridges anionic phosphate groups of the nucleic acids. When injected into the 
systemic circulation, positively charged nucleic-acid nanoparticles will further aggregate 
through interaction with erythrocytes and other negatively charged serum proteins such 
as albumin, IgM, IgG, complement C3. Ho et al. showed that DNA-polyplexes formulated 
with Turbofect© (poly(2-hydroxypropyleneimine)) aggregates rapidly via the first 
mechanism unless its formulation is confined within picoliter volume droplets generated 
by a microfluidic chip.59 Li et al. also showed that the particle size of non-pegylated 
liposome-protamine-DNA complexes (LPD) increases from 135nm to 647nm after they 
were mixed with serum.23 Particle aggregation creates a problem because upon reaching 
the target organ, they become too large to extravasate out of the blood capillaries 
through the endothelial fenestrations to get to the underlying cells (Figure 2).  
19 
 
Blood vessels in the liver and spleen are organized into sinusoids, where endothelial 
fenestrations are wider and blood flows slower. This allows nanoparticles that remained 
stable (or did not appreciably aggregated) to extravasate into the tissues reaching the 
inner hepatocytes in the liver or white pulp cells in the spleen (predominantly T cells, 
DCs and macrophages). Aggregated particles that are too large to pass through the 
endothelial fenestrations they will be cleared from the blood stream by Kupffer cells 
found in between hepatocytes in the liver lobules (Figure 4a) and marginal zone 
macrophages (MZ) in the spleen (Figure 4b) via scavenging receptor-mediated 
endocytosis. The particles distributed via intravenous administration are unevenly 
distributed. For example, 60% and 55% of intravenously injected non-pegylated LPD 
lipopolyplexes56 and PEI-25K-DNA polyplexes 60 accumulated in the liver. Similarly, 80% 
and 10% of mRNA lipopolyplexes administered intravenously via the tail vein 
accumulated in the liver and spleen respectively.40  
As lipid-based nanoparticles are the most frequently evaluated formulation for mRNA 
immunization, we will further elaborate on its in vivo distribution. Lipid-based 
nanoparticles that are distributed to the spleen after IV administrations are sequestered 
in the splenic marginal zone after 12 hours and gradually move out into the white pulp (T 
cell region) after 24 hours (Figure 4c). At the 24th hour time point, an increased infiltration 
of CD11b+ and CD11c+ cells in the spleen is detected.61 At this time, about 25% of 
splenic CD11b+ cells and 15% of splenic CD11c+ cells are reported to have taken up 
lipopolyplexes (e.g. LPDs) distributed to the spleen after intravenous administration,61 
but only about 4% of CD11c+ cells express the encapsulated GFP mRNA.40 The 
transfection efficiency of CD11c+ cells is increased (from 4% to 13% based on GFP+ 
cells) when mRNA lipopolyplexes are functionalized with mannose.40 As macrophages 
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can also present antigens to T cells after being activated via a ROS mediated pathway62 
directly by themselves or indirectly through DCs, the total number of antigen presenting 
cells targeted by intravenous administration is actually quite reasonable. Still, this may 
not be an efficient strategy because a significant amount of nucleic acid is actually taken 
up by the liver and not the spleen. These nucleic acids that are distributed to the liver are 
also very poorly expressed,23, 60 presumably degraded by Kupffer cells.  Similarly, splenic 
MZ and immature DCs both engender highly degradative endocytic pathways27 that 
break down intracellular cargoes destined for MHC class II processing through the 
endosome-lysosome pathways (Figure 2).63 Hence, it is important that nanoparticles 
must be able to escape from the early/late endosome efficiently, otherwise a large 
proportion of the mRNA nanoparticles taken up by the DCs and macrophages in the 
spleen will be degraded. In addition, due to a lobe-sided biodistribution, large 
nanoparticle doses will be required to achieve adequate splenic transfection, which may 
lead to gene carrier mediated toxicities. Nevertheless, there have been numerous 
reported CTL assay that proved intravenous administered mRNA nanoparticle 
formulations can activate antigen specific CTLs.37, 39-41, 64, 65 These studies will be 
reviewed in later sections. Whether such CTL levels are robust enough to achieve 
therapeutic responses comparable to mRNA-DC vaccine remain to be seen. To 
summarize, for systemic administration of mRNA nanoparticles,  it certain that the 
nanoparticles will be taken up by antigen presenting cells in the liver and spleen. 
However, a large dose is necessary because the particles are distributed poorly to the 
spleen and DCs are not efficiently transfected.  Hence for IV administered mRNA 
nanoparticle vaccine formulations, improving splenic distribution, transfection efficiency 
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of splenic DCs and evaluating these parameters against therapeutic outcome are issues 
that should be addressed to advance the field.  
 
 
 
Figure 4. Histology of murine liver, skin and spleen 
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 (a)  Cross section of murine liver sinusoids. Systemically administered non-pegylated 
fluorescently labeled LPD lipoplexes trapped within the sinusoids of liver lobules and taken 
up by Kupffer cells (white arrows).66 Red: LPD, Blue: DAPI, Green: Phalloidin.  
(b)  Immunostain of mouse spleen’s cross-section showing locations of white pulp (DCs & T 
cells) and marginal zone. Blood flow direction from white to red pulp. (Blue: marginal zone 
macrophages; green: marginal metalophillic macrophages; red: red pulp macrophages). 
 (c)  Localization of non pegylated LPD in mouse spleen 12 and 24 hours after intravenous 
administration.67 
 (d)  Anatomy of the skin. (a epidermis, b dermis, c skin (panniculus) muscle, d subcutaneous 
connective tissue, and e skeletal muscle of trunk).68  Reproduced with permission.68,66,67. 
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1.2.3.3 Subcutaneous Administration 
In subcutaneous administration, the objective is to deliver mRNA encapsulated 
nanoparticles to lymph node DCs through the lymphatic system (and transfecting them), 
or alternatively transfect dermal dendritic cells already present in the skin. Although 
intradermal injection may be more favourable due to the prevalence of dermal DCs, 
administering a single dose precisely within the thin layer of dermis (‘b’ in Figure 4d) may 
be a challenging procedure in mice models, where most experimental vaccination 
studies are conducted. The subcutaneous space is a non-cellular region (‘d’ in Figure 4d) 
found between the skin and skeletal muscles (‘c’ and ‘e’ in Figure 4b) that can be easily 
accessed through skin folding. Consequently, extracellular barriers associated with this 
subcutaneous vaccination are related to poor targeting of dermal dendritic cells and 
trafficking efficiency of particles to the lymph nodes.   
Studies conducted to investigate the determinants of lymphatic trafficking reveal that that 
particle size, charge and colloidal stability are factors influencing the rate of transport 
through the subcutaneous space. Although particles in these studies were made with a 
wide range of materials, there is a consensus that ultra-small particles (<50nm) are the 
most efficiently transported69, 70, while those ranging from 100nm to 300nm can also 
reach the lymph nodes64, 69-75. Proteins (~7% by mass, predominantly albumins and 
globulins) are also present in interstitial fluids76 but their concentrations are significantly 
lower compared to blood and as a result particle aggregation may not be a significant 
impediment in subcutaneous vaccination.  
Another observation made by Moghini et al. 72 using neutral DOPC liposomes is that 
increased particle hydrophilicity (via pegylation) enhanced trafficking efficiencies through 
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reduced non-specific interactions with interstitial proteins. In a similar study, Zhuang et 
al. 71 showed that a high cationic charge on DOTAP liposomes (-potential: +43mV) 
significantly reduce its trafficking capacity (Figure 5a) compared to pegylated DOTAP 
liposomes (-potential: +15mV). Pegylated liposomes appeared in the lymph node as 
soon as 30 minutes after administration compared to 4 hours (non pegylated), confirming 
a passive lymphatic transport mechanism (note: transport of Evans Blue subcutaneously 
through the tail base labels the inguinal lymph node within 30 minutes77). Notably in both 
studies, increasing PEG length accelerated particle transport, but they could not be 
efficiently retained in the lymph node (Figure 5b). Beside liposomes, polymeric particles 
composed of chitosan/heparin (size: 200nm to 1m, -potential +25mV) can be found in 
popliteal lymph nodes 45 minutes after footpad injection (Figure 5c).73 
Although nodal transfection mediated by subcutaneously administered mRNA 
nanoparticles have not been well studied, transfection efficiency and transgene 
expression kinetics mediated by mRNA nanoparticles at the subcutaneous site has been 
reported. mRNA subcutaneously administered in nanoparticle form is not only more 
poorly expressed, but is also expressed over a shorter period of time compared to naked 
mRNA at the site of injection.78 The poor local transfection performance may be caused 
by entrapment within the extracellular matrix, while naked mRNA can diffuse through the 
ECM to reach muscle and dermal cells on each side. Although particle properties were 
characterized (250nm in 50% serum, -potential -15mV), their transport to the lymph 
node has not been determined. On the other hand, the fact naked mRNA can mediate 
high transfection efficiencies via subcutaneous administration shows that it can remain 
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relatively stable in the subcutaneous space. However, it could not remain stable enough 
to be transported through the lymphatics to the lymph node.36  
Despite of a lack of direct evidence of nodal DC transfection from subcutaneously 
administered mRNA nanoparticles, antigen specific CTL cell responses are efficiently 
induced37, 38, 41 and anti-tumour therapeutic responses have been reported.37  These 
studies indicate that dermal DCs may play a significant role in the induction of immunity 
for subcutaneously injected mRNA nanoparticles.  
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Figure 5. Nanoparticle trafficking after subcutaneous administration 
 
(a) Lymph node trafficking of DOTAP liposomes (0%/1%/5% PEG) over six time periods.71  
(b) Distribution of DOTAP Liposomes (0%/1%/5% PEG) in the lymph node over time measured 
based on radioactivity.71  
(c) Popliteal lymph nodes isolated 45 minutes after injection of heparin-polylysine particles. 
Green: polylysine, Blue:Lyve-1 (lymphatic endothelial cells), RED: B220(B cell marker).73   
(d) Anatomy of the skin. (a epidermis, b dermis, c skin (panniculus) muscle, d subcutaneous 
connective tissue, and e skeletal muscle of trunk).68  
Reproduced with permission.68,71,73  
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1.2.3.4 Intranasal Administration 
In intranasal administration, particles are directly delivered to lymphoid tissues located in 
the nasal cavity (Figure 6a) avoiding barriers posed by systemic or lymphatic transport 
discussed earlier. Immune cells within these lymphoid tissues are arranged in an 
organized follicular tissue structure (nasal associated lymphoid tissue, Figure 6b)79 found 
directly under the nasal epithelium. The objective is to deliver particles through the thin 
nasal epithelium to the immune cells composed of not only B and T cells, but also 
dendritic cells (Figure 6c, 6d). The nasal epithelium above the NALT is a single layer of 
epithelial cells littered with microfold cells (M cells). M cells are of interest in nasal 
particle delivery because they translocate particles from the epithelium to the underlying 
NALT.80 Particles translocated by M cells may be taken up by NALT cells, drained 
passively to the cervical lymph nodes through lymphatic vessels or transported actively 
through DCs that took up these particles.  Particle size (and aggregation issues) may not 
be a significant barrier to transport across the nasal epithelium because M cells are 
known to translocate particles with sizes up to several microns.81 Nevertheless, many 
studies show that particles at or below 1 micron tend yield better functional outcomes.81-
83 As the epithelial surface is negatively charged due to the presence of the glycocalyx, 
particles with net positive charges have been reported (and expectedly so) to mediate 
better immune responses. Ironically, particles with higher negative zeta potentials (at 
least -25mV) can also be efficiently transported by M cells.82, 83 It appears that decreased 
ionic concentration of the buffer used to suspend the particles can increase M cell 
uptake, through potentiating particle charge density.82  
The relatively permissive transport mechanism through the nasal epithelium is 
undermined by the fact that fluid instilled into the nasal cavity is rapidly clear from the 
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nose shortly after administration (80% by mass within the first hour).84 Therefore 
increased particle adhesion onto the nasal walls, especially through the use of 
mucoadhesive materials such as chitosan can enhance immune responses albeit at a 
very high dose.85, 86 Although mucoadhesion increases the residence time of particles on 
the nasal epithelium, it can also impede their movement through the mucus, making it a 
property that needs to be carefully applied to achieve optimal results.87 We have 
reported nasal transfection with lipid based mRNA nanoparticles (180nm, +40mV in 
water).78 Although these particles were cleared almost as quickly as naked mRNA, 
luciferase expression peaked at the 4th hour and remained detected for up to 24 hours 
compared to naked mRNA which was only detectable at 4th hour post administration.78 
Similar expression kinetics was observed in another study where luciferase mRNA 
surface adsorbed on pegylated core shell nanoparticle (280nm, +40mV in water) were 
intranasally administered.88 
Unlike drug loaded particles, cellular uptake is a requirement for gene loaded particles to 
exert a biological effect.  As mentioned earlier, the mucus barrier is one that should not 
be underestimated because a mucus layer as thin as 20nm can block particle access to 
M cells.89 Hence particle properties that facilitate transport across the mucus will 
enhance nasal delivery of nanoparticle vaccine. It has been shown that pegylated (PEG 
length ~5kda) or medium sized particles (200nm and 500nm) diffuse through mucus 
more efficiently than non-pegylated or smaller particles (100nm).87 Since the mucus 
barrier of NALT in a healthy subject is relatively thin, it is uncertain the pegylation 
approach will enhance delivery efficiencies. 
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In summary, nasal administration of mRNA nanoparticle vaccine is an attractive strategy 
for tumour vaccination due to its non-invasive nature. Recent studies have demonstrated 
that nasal transfection using mRNA encapsulated in nanoparticles is a feasible concept.  
Further studies are warranted to ascertain if this route of delivery can induce an anti-
tumour response. M cell transport efficiencies may be enhanced by using highly 
negatively charged particles, increasing residence time of the particles on nasal 
epithelium as well as enhancing mucus penetrating power of the nanoparticles. The 
incorporation of such properties into mRNA nanoparticles will help overcome 
extracellular barriers associated with nasal nanoparticle vaccine delivery.  
.  
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Figure 6. Nasal Associated Lymphoid Tissue (NALT) 
 
(a) Location of NALT in mouse (top; T: turbinates, N: NALT) and human (bottom; Red: adenoids; 
Green: tubal tonsil). T: Turbinate; N: NALT. cross section of  
(b) Cross section of nasal cavity showing location of NALT in mouse.79 (NS: nasal septum; ND: 
nasal cavity; ET: turbinate)  
(c) NALT stained for CD11c+ DCs (red).90  
(d) Cross section of human adenoid tonsil stained for plasmacytoid DCs (brown).91   
Reproduced with permission.91,90,79 
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1.2.3.5 Cytosolic Gene Delivery of mRNA in Dendritic Cells 
Upon reaching the target organ, mRNA nanoparticles need to be efficiently taken up by 
antigen presenting cells, mediate endosome escape and single stranded mRNA has to 
be released from the gene carrier for protein translation. It was concluded at a very early 
stage that DCs can only be poorly transfected with lipoplexes.8 Based on %GFP+ cells, 
transfected immature and mature human DCs using DMRIE-C were 7.5% and 4%, 
respectively. In the same study, transfection mediated by electroporation was 63% and 
33%, respectively. Consequently, there was little interest in chemical mediated 
transfection of DCs. But significant advances in gene carrier development were made in 
the past decade through systematic investigations into the structure-to-function 
relationship of gene carriers. In this section we will review gene carriers that have been 
applied to mRNA transfection of DCs. In vitro transfection is commonly studied using 
DC2.492 and JAWS II (ATCC) cell lines, as well as primary murine bone marrow derived 
dendritic cells (BMDCs) and human monocyte derived DCs. 
Perche et al.40 developed a targeted lipopolyplexes prepared by addition of 
mannosylated and histidylated liposomes to mRNA pre-condensed with PEG and 
histidine modified polylysine based on the LPD concept.93 Lipids and polylysine, the 
building blocks of LPD, are custom synthesized incorporating imidazole moieties to 
enhance endosome escape via the proton-sponge effect. A portion of the lipids are also 
conjugated with mannose to enhance targeting. Interestingly, the lipid tail is linked to it 
head group via a phosphoramide bond to improve biocompatibility. Transfection 
efficiencies based on GFP+ cells against DC2.4 in Opti-MEM using these targeted 
lipopolyplexes is significantly higher (60%) compared to the same lipopolyplexes without 
mannosylated lipids (40%).  
32 
 
Cheng et al.94 developed a series of “DPE” triblock co-polymers composed of a 
DMAEMA (dimethylaminoethyl methacrylate) segment for cationic-mediated mRNA 
binding, a PEGMA (polyethylene glycol methacrylate) segment to impart colloidal 
stability and a DEAEMA-co-BMA (copolymer of diethylaminoethyl methacrylate and butyl 
methacrylate) segment to achieve pH sensitivity for endosome escape. Transfection 
efficiencies against DC2.4 cells in serum free media reached 50% (GFP+).  
Su et al.88 developed a formulation where mRNA is delivered via lipid-enveloped pH 
sensitive core-shell nanoparticles. Based on a similar concept reported for DNA 
vaccine95, mRNA is electrostatically adsorbed onto the surface of pegylated cationic 
nanoparticles composed of pH-sensitive core and a PEG/DOTAP/DOPC lipid shell. 
These particles were efficiently taken up by 80% of DC2.4 in the presence of 10% serum 
and but only 30% were transfected. This discrepancy is likely attributed to degradation of 
mRNA, which may not be well protected via surface adsorption.  
Surprisingly, commercially available mRNA transfection reagents are also relatively 
efficient in DC transfection. Mockey et al.43 used lipofectamine to transfect JAWS II cells 
with luciferase mRNA to study the potentiation of mRNA translation by the length of the 
poly-A tail. Phua et al.78 used Stemfect mRNA transfection reagent to study the 
transfection efficiency and transgene expression kinetics of mRNA in naked and 
nanoparticle format. Based on %GFP+ cells, the transfection efficiencies against 
immature BMDC and immature human monocyte derived DCs were 63% and 52% 
respectively, while that against DC2.4 and JAWS II cells were 98% and 80%, 
respectively. Kariko et al. 48 used Mirusbio Trans-IT mRNA transfection reagent to study 
enhancement in protein translation mediated by luciferase mRNA synthesized with 
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unlicensed DCs that do not provide co-stimulation via CD70/80/86) are eventually 
deleted.97  It is therefore evident that antigens have to be presented on both MHC I and II 
for proper DC and T cell activation to achieve a robust cellular immune response.  
In contrast to a classical infection, antigen proteins are instead derived from within the 
cytoplasmic compartment. Although in this way antigen can be efficiently presented on 
MHC class I molecules, they tend to be poorly presented on MHC class II molecules, as 
only 10-30% of peptides bound to MHC II are derived from cytoplasmic and nuclear 
proteins.96 It is now known that cytoplasmic antigens are presented on MHC II via 
various autophagy mechanisms, in particular, the chaperone-mediated autophagy is 
major pathway involved in MHC II presentation of translated antigen protein. In this 
pathway, cytoplasmic chaperones Hsc70 and Hsp90, together with lysosomal 
transmembrane protein (LAMP) selectively shuttles epitopes into lysosomes, effectively 
infiltrating into the MHC II pathway.96 To enhance mRNA tumour vaccination, the 
chaperone-mediated autophagy pathway has been exploited to increase MHC II-peptide 
presentation. It has been shown that a single LAMP-1 or DC-LAMP16 sequence can be 
cloned into the cDNA template so that the mRNA is eventually translated as a LAMP 
tagged protein (Figure 2). Co-delivering mRNA encoding both LAMP tagged and 
untagged protein has been shown to be effective in enhancing anti-tumour immunity in 
colorectal and melanoma immunotherapy models.12, 39, 98 
In summary, the lack of MHC II presentation in mRNA vaccination is problem that has 
been overcome through co-delivery of LAMP-tagged mRNA to access the MHC II 
pathway. Besides LAMP-tagged mRNA, co-delivery of multiple mRNAs encoding 
additional adjuvants, such as the TriMix19 or GM-CSF37 is a proven concept that has 
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fibroblasts and epithelial cells. TLR3, which senses double stranded RNA (derived from 
internal hairpin structures of mRNA), trigger the secretion of both type I interferon via a 
TRIF dependent pathway as well as pro-inflammatory cytokines via the MyD88 
pathways. TLR7, which senses single stranded RNA, triggers the secretion of 
inflammatory cytokines via MyD88 pathway. In addition to endosome associated immune 
receptors, cytosolic retinoic acid inducible gene-I (RIG-I) receptor 100 can be activated by 
triphosphates at the 5’ end of uncapped mRNA leading to the secretion of type I 
interferon (Figure 2). Although it is a common practice to cap the 5’ end of mRNA with an 
anti-reverse cap analogue during in vitro transcription, capping efficiency is usually about 
80%, leaving exposed 5’ triphosphates from uncapped fraction available for RIG-I 
activation.  MDA5 is another cytosolic receptor sharing the RIG-I signalling pathway that 
can be activated by long-double stranded RNA (such as self-replicating RNA, which has 
re-emerged recently in the vaccine field). 101  
Pro-inflammatory cytokines induced from mRNA have been identified as TNF-,19,102 IL-
1,36 IL-12,36,103, 104 IL-6,19,36, 102, 104, 105 IL-8.105 Similarly Type 1 interferon induced from 
mRNA are IFN-100, 102, 103, 106 and IFN-.100, 102 Interestingly, chemokines such as GRO 
(Growth-Regulated Oncogene), MCP-1 (Monocyte Chemoattractant Protein-1), RANTES 
(Regulated on Activation, Normal T cell Expressed and Secreted) and MDC 
(Macrophage-Derived Chemokine) have also been reported when peripheral blood cells 
are pulsed with naked mRNA.105 These secretions exert not only an immediate anti-viral 
response (innate immunity), but also adaptive immune responses by facilitating the 
maturation of professional antigen presenting cells (dendritic cells, B cells, activated 
macrophages) through up-regulation of MHC II and co-stimulatory molecules (CD80, 86) 
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as well as a change in chemokine receptors.  The secretion of Type-1 interferon induced 
by innate immune response to mRNA has recently been shown to be counterproductive 
in the induction of antigen specific T cells when mRNA is delivered via DOTAP/DOPE 
lipoplexes.41 This study confirms the idea that not all “self-adjuvant” effects derived from 
mRNA facilitate the development of cellular immunity.  
The immunogenicity of mRNA has been highlighted in recent years due to increasing 
interest in their therapeutic application outside immunotherapy. A better understanding 
on the structural103, 108 and molecular basis33, 48 for mRNA’s biological stability and 
mechanism of immune activation have led to increased translational capacity mRNA and 
boosted its potential for gene therapy applications. However, as reports describing non-
modified mRNA as “non-immunogenic” exist,12,45 the impression that mRNA is highly 
immunogenic has to be put into perspective. It has been shown that mRNA delivered by 
electroporation is not efficient in mediating DC maturation. DC maturation marker CD83 
(<30%) and costimulatory molecule CD80(<40%)8, 14 are both poorly upregulated in 
human monocyte derived DCs in vitro, even though the transfection efficiency based on 
GFP expression is 76%. However, the other co-stimulatory molecule CD86 is relatively 
well up-regulated (>70%), indicating that transfected DCs can be partially matured with 
mRNA. CD86 up-regulation of a similar magnitude is also observed in nodal DCs, when 
mRNA is directly injected into inguinal lymph nodes. However this study did not report 
the transfection efficiency based on GFP+ cells, staining of CD83 and CD80, making it 
difficult to conclude extent of DC maturation. Overall, these data suggest that partial 
maturation may only occur in mRNA-loaded DCs in vitro, compared to >90% maturation 
(for CD 80,83,86) yield in cytokine treated DCs. 
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 An inherent advantage of mRNA nanoparticle vaccine is that its overall 
immunogenicity can be modified by the gene carrier. When delivered in nanoparticle 
format, CD80 and CD86 of human monocyte derived DCs (pulsed with mRNA-lipofectin) 
were both more efficiently up-regulated (>90%) compared to cytokine treatment (>80%).  
CD83 expression, however, remained relatively muted.65 Interestingly, CD80 and CD86 
are both up-regulated (>50%) by lipofectin liposomes alone while CD83 expression 
remained low (4%). As the transfection efficiency mediated by lipofectin against human 
monocyte derived DCs is unlikely to be >90%, this response is more consistent with 
immunostimulating effects of cationic liposomes via ROS mechanism, a topic that has 
been comprehensively reviewed.75,109 In another study, Rettig et al. compared the 
cytokine secretion profile when human peripheral blood mononuclear cells (PBMCs) are 
treated with -Gal RNA either in naked form or encapsulated by protamine. Using a 
cytokine array, it was observed that -Gal RNA nanoparticles mediated significantly 
higher levels of IL-6, IL-8 and MCP-1 compared to naked mRNA,105 suggesting that 
cytokine secretion can also be affected by the addition of protamine. Protamine 
condensed mRNA also induced CD86 on dendritic cells, but the transfection efficiency of 
the mRNA is abrogated. Similarly, Oliwia et al. also showed that mRNA lipoplexes 
induced high levels of IL-6 and IL-12 and TNF- in murine lungs following intranasal 
instillation.110 Unfortunately in this study, cytokine secretion from liposome alone or 
naked mRNA was not available. Nevertheless in another study, subcutaneously injected 
mRNA-DOTAP/DOPE liposomes but not the liposomes alone, induce high levels of IL-6, 
IL-1 and type I interferon in DCs.41 This lack of cytokine induction by empty liposomes is 
consistent with the adjuvant effects of DOTAP-based vaccines,109 and an interesting 
contrast between lipid and polymeric gene carriers. 
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In an effort to evaluate the use of modified RNA for immunotherapy, Pollard et al. 
investigated the effects of IFN- on T cell response.41 Surprisingly, IFN knockout mice 
immunized subcutaneously with DOTAP/DOPE mRNA lipoplexes develop more robust 
antigen specific T cell responses compared to wild type mice. Although results coming 
from knock out models are encouraging, a direct confirmation is needed from wild type 
models immunized with modified mRNA to confirm its utility in immunotherapy.  
Gene carriers may also decrease the overall immunogenicity of the mRNA formulations. 
Uchida et al. show mRNA encapsulated in nanomicelles (PEG-polyamino acid block co-
polymer) administered into the central nervous system induces lower levels of IL-6, TNF-
, IFN-4 and IFN-1 from neural tissues compared to naked mRNA.102 
To summarize, immunotherapies that apply mRNA encapsulated in nanoparticles may 
benefit from immunogenicity or lack thereof of gene carriers. Immune stimulating 
properties of mRNA in terms of the mechanism of activation and the extent to which it 
can modify DC phenotype are well characterized. But there is still a knowledge gap on 
how molecular structure of the gene carrier modifies mRNA’s basic immunogenicity. 
Lipid-based formulations are highly capable of upregulating costimulatory molecules 
such as CD80/86, but are poor in inducing DC maturation and cytokine secretions 
necessary for a complete T cell activation. Protamine can upregulate CD86 expression 
and also induce high levels of proinflammatory cytokines. PEG-poly amino acid 
nanomicelles, on the other hand, attenuate immune response 
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1.3 mRNA nanoparticle vaccine delivery systems for tumor immunotherapy. 
 
In the previous sections, we discussed a framework for mRNA nanoparticle delivery: 
namely (1) gene delivery, (2) immune activation and (3) MHC processing. Despite 
numerous reports on mRNA nanoparticle (mRNA-NP) delivery, only a handful studied its 
therapeutic efficacy in terms of either immune responses (CTL assay/IFN- secretion) or 
overall survival. In this section, we review these studies (listed in Table 1) highlighting 
current progress in mRNA-NP mediated tumour vaccination and provide a perspective 
on the bottleneck in this niche but exciting area of research. 
The first attempt in mRNA-NP vaccine was reported in 1993 by Martinon et al.111 using 
anionic liposomes composed of phosphatidylcholine(PC)/ phosphatidylserine(PS)/ 
cholesterol. mRNA encoding influenza nucleoprotein was encapsulated into liposomes 
by the hydration method. This formulation method was inefficient and yielded about 10% 
encapsulation efficiency.111 Even so, antigen specific CTL response was induced if the 
particles were administered via IV or SC but not IP.111 IP vaccination route also failed to 
induce CTL response in another study where mRNA was encapsulated in Unifectin-
based lipoplexes and lipopolyplexes.38 The authors speculated the reason for ineffective 
IP route was due to either particle aggregation or an insufficient number of peritoneal 
antigen presenting cells.111 This study is interesting because these pH insensitive anionic 
liposomes not only do not interact well with negatively charged cell membranes, they are 
also inefficient in endosome escape (Figure 2). Yet they mediate antigen specific CTL 
responses indicating that mRNA had been translated by antigen presenting cells. This 
PS containing mRNA formulation may have been taken up by antigen presenting cells of 
the monocyte-phagocyte system via PS receptors. In addition, the anionic nature of the 
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lipoplexes can resist opsinin-mediated aggregation in the blood when administered IV, 
and since these liposomes were previously extruded with a 200nm membrane, they can 
also efficiently drain to the lymph nodes. This formulation will be promising if the 
encapsulation efficiency is increased and if pH sensitive molecules are incorporated.. 
Hoerr et al. demonstrated that the use of liposomes (Unifectin) protected mRNA from 
nuclease-mediated degradation in vivo and significantly increases CTL response via IV 
route, but failed to induce any CTL response via the IM and IP routes.38 In addition, 
despite evidence showing small amounts of protamine can protect naked mRNA from 
nuclease degradation (for about 30 minutes), mice subcutaneously immunized with 
mRNA formulated with protamine alone (without Unifectin) did not enhance CTL 
response compared to unprotected naked mRNA. 
Hess et al. first reported survival data from mRNA nanoparticle tumour vaccination.37 In 
this detailed study, OVA mRNA encapsulated in DOTAP liposomes was intradermally 
administered into mice ear pinnae twice (14 days apart) in a prophylactic immunotherapy 
model, followed by subcutaneous tumour challenge with E.G7-OVA cells. Splenic CD8+ 
T cells from immunized mice demonstrated lytic activities both in vitro (CTL assay) and in 
vivo (adoptively transfer of CFSE labelled OVA pulsed splenocytes). These mice also 
experienced significant delay in tumour onset and progression against E.G7-OVA 
tumour challenge through Day 16. The formulation applied in this study was DOTAP 
lipoplexes prepared by mixing mRNA with DOTAP liposomes in PBS. These lipoplexes 
were not characterized for size and zeta potential in this study. Nevertheless, the use of 
PBS would have caused aggregation because it has been reported that DOTAP 
lipoplexes aggregate when they are formulated in the presence of salt.112. 
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Particle aggregation, as mentioned earlier, reduces extracellular and intracellular gene 
delivery efficiencies. And this was likely reason for a higher CTL response from IV route 
compared to ID route and an absence thereof from SC route (tail base). Also, 
aggregated particles administered IV can still be taken up by macrophages in the liver 
and spleen, develop into antigen presenting cells through ROS mediated activation (by 
DOTAP) and transfer the antigen to endogenous DCs or activate T cells directly. 
Intradermal administration induced a dose dependent CTL response because a small 
fraction of mRNA lipoplexes were still bioactive and could transfect dermal DCs, which 
eventually induces the CTL response. As this is a small fraction of the given dose, a 
larger dose may lead to higher DC transfection and presumably higher CTL response. In 
this review, we are able to correlate observed CTL responses to particle properties of 
lipoplexes because they have been characterized in other studies under similar 
conditions. As shown in Table 1, mRNA nanoparticle tumour vaccination studies are 
often reported without much information about particle properties. To optimize 
therapeutic outcome, particle characterization such as size, zeta potential measured 
under the applied physiological conditions should be an important aspect of future 
immunotherapy experiments. 
In the same study (Hess et al.), it was observed that CTL response from mRNA 
encapsulated in DOTAP/DOPE is also 4 times higher than in DOTAP liposomes. This 
shows that the inclusion of DOPE, a helper lipid with fusogenic property, facilitated 
intracellular gene transfer to antigen presenting cells.113 This shows, at least in the 
DOTAP-based mRNA liposomes, that endosome escape is a rate limiting step for 
immune modulation. In addition, co-delivery of OVA mRNA with either GM-CSF (to 
attract DCs), CD80 (co-stimulatory molecule) and IL-2 (T cell proliferation) was 
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evaluated. It was found that CTL response was enhanced with GM-CSF mRNA, but not 
CD80 or IL-2 mRNA. These results demonstrate the threshold levels of GMCSF needed 
to enhance immune response is much lower than CD80 and IL-2. It also re-affirms that a 
co-delivery system is the optimal mRNA nanoparticle tumour vaccine. 
Mockey et al. also reported anti-tumour efficacy of mRNA nanoparticle vaccination using 
histidylated lipids optimized for mRNA delivery.39 These phosphoramide lipids were 
synthesized with single histidine head groups to facilitate endosome escape via proton 
sponge effect. Mannosylated lipids (11% molar ratio) were later incorporated in the 
formulation (Man11-LPR) to enhance uptake.114 The colloidal stability of mRNA 
nanoparticles formulated with these lipids in physiological salt concentration and in 
serum is unknown although particles were about 150nm in size (-potential +14-18mV) 
in 10mM Hepes. But given its almost identical in vivo biodistribution with LPD, their 
colloidal stability may be the similar to unpegylated LPDs. In Mockey et al., MART-1 
(Melanoma antigen recognized by T-cells 1) mRNA encapsulated in these histidylated 
lipopolyplexes is intravenously administered into mice via tail vein twice (7 days apart) in 
a prophylactic model, followed by a subcutaneous tumour challenge with B16 F10 cells. 
Developed tumours progressed more slowly in immunized mice compared to control 
mice vaccinated with luciferase mRNA nanoparticles.  In a subsequent study by Perche 
et al.,40 MART-1 mRNA encapsulated in Man11-LPR or non-mannosylated LPR 
formulations were re-evaluated in the prophylactic B16 F10 melanoma immunotherapy 
model. The median survival of mice immunized with MART-1 mRNA nanoparticles 
formulated with Man11-LPR was 5 and 10 days longer than mice immunized with non-
mannosylated LPR and NaCl controls, respectively. Although the effectiveness of Man11-
LPR in a therapeutic immunotherapy model remains to be determined, this study 
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demonstrated that the presence of a targeting ligand improved overall therapeutic 
efficacy through enhanced uptake of nanoparticles by antigen presenting cells. 
In this section, we reviewed studies that evaluated mRNA nanoparticle 
formulations for tumour vaccination. Although nanoparticle properties are not well 
characterized in these immunotherapy studies, it can be concluded that the use of 
mRNA nanoparticles can induce consistent CTL responses. Evidence shows that 
nanoparticle delivery of mRNA tumour vaccination is a feasible research direction and 
much work has yet to be done. 
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Table 2. mRNA nanoparticle tumor vaccination studies evaluated for T cell response or survival 
IV: intravenous (tail vein); SC: subcutaneous (base of tail); ID: intradermal (ear pinnae); IM: intramuscular; IP: intraperitoneal. “+” and “-
“respectively indicate statistically significant and insignificant result compared to controls. “++” indicates results are significantly higher 
than “+” samples reported in the same study. 
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1.4 Conclusions 
 
Advances in the past decade have deepened our understanding of mRNA’s biological 
stability, immunological properties and provided extensive evidence to support the need 
for engineering innovations to deliver mRNA for genetic vaccination. In this review we 
discussed the physical stability of mRNA in aqueous buffers and clarified the technical 
possibility of subjecting mRNA to engineering manipulations. Presently, mRNA 
administered directly in vivo benefits from being encapsulated with gene carriers in 
nanoparticle format and a growing number of published studies have looked at the 
feasibility of applying nanomedicine concepts to mRNA tumour vaccination. Although a 
few deliberate attempts were made on the rational design of mRNA gene carrier,40, 88, 94 
most have not been functionally evaluated in vivo for immune or therapeutic response.40, 
94 Instead, off-the-shelves gene carriers are the most frequently used to encapsulate 
mRNA and evaluated for their ability to stimulate antigen specific T cell responses, often 
without adequate particle characterization. Clearly, the optimal mRNA gene carrier for 
tumour vaccination application has yet to be determined. But given the sustained 
interests in this field, the discovery of better mRNA formulations will no doubt accelerate 
in the near future. Based on our knowledge on gene delivery and mRNA immunotherapy, 
we discussed a model frame work that highlights the barriers to the development of a 
robust anti-tumour immunity mediated by mRNA encapsulated in nanoparticles, and 
reviewed studies that evaluated therapeutic outcome of mRNA nanoparticle vaccination. 
mRNA nanoparticle tumour vaccination can be advanced if we bring nanomedicine 
closer to mRNA immunotherapy. 
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2 Specific Aims 
2.1 Significance 
 
A major reason for the failure of direct in vivo injection of naked mRNA is due instability 
caused by extracellular nucleases. Consequently, direct mRNA vaccination via 
administration of naked mRNA is found to be effective only when it is directly injected 
into the lymph nodes [42, 46]. These studies demonstrate that when naked mRNA is 
delivered directly to lymphoid tissues (e.g. lymph nodes) where antigen presenting cells 
(DCs, macrophages), T and B cells reside in an organized way, anti-tumor immune 
responses can be effectively generated. However, intranodal vaccination is highly 
invasive in mice and technically challenging in humans. Moreover, repeated 
administration (DC vaccine is administered 3 to 4 times biweekly in humans) and hence 
multiple surgeries, are required to acquire immunity making it relatively unattractive for 
clinical translation.  
Although this limitation can be addressed by formulating mRNA into nanoparticles with 
gene carriers, in vitro transfection efficiency (based on %GFP population) on primary 
dendritic cells mediated by mRNA encapsulated in nanoparticles has been poor and as a 
result, only a few studies applied mRNA nanoparticles as a proof-of-concept for tumor 
vaccination. Hence there is a need to identify better mRNA formulations that have the 
ability to transfect primary dendritic cells efficiently. 
Although the use of mRNA nanoparticles renders a shift away from cell based 
vaccination (mRNA transfected DCs), the latter is already a more matured technology 
that widely reproduced in the clinics worldwide. mRNA transfected DC vaccine is an 
effective, but also a laborious, time consuming and costly method to induce anti-tumor 
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immunity. The average time required to generate DCs from human peripheral blood 
monocytic cells (PBMCs) is 6 days. This is in addition to 4-6 hours of cell isolation and 
overnight culture with specially formulated media to mature antigen loaded DCs. It is only 
recently known that DCs are known to be capable of “cross-dressing” i.e. Balb/c DCs 
(mice that are incapable of presenting SIINFEKL (OVA) peptide on MHC I molecules) 
pulsed with OVA peptide, mediate the expression of MHCI-OVA complex in naïve 
C57Bl/6 derived DCs (mice capable of presenting OVA peptide on MHC I molecules).115 
In addition, Yewdall et al. provided direct in vivo evidence that demonstrates that ex-vivo 
transferred DCs do not significantly activate CD8+ T cells, but instead act as vehicles that 
transfer the antigens to endogenous DCs.116 This raises the possibility of using 
alternative cell types for mRNA cell based vaccination, which may obviate extensive 
manipulation and culture required for mRNA-DC vaccination. 
In conclusion, the direct in vivo mRNA vaccination using nanoparticles as well as the use 
of alternative cells types that obviates logistical requirements of mRNA-DC vaccine are 
both viable approaches that may facilitate broad translation of mRNA based vaccination. 
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2.2 Thesis Objective 
 
A significant bottle neck to broad translation of mRNA cell based vaccination is the need 
for extensive cell manipulation and culture to derive matured mRNA transfected DCs 
from autologous blood monocytes. The objective of this thesis is to address this 
bottleneck to facilitate broad translation of mRNA vaccination. As shown on Figure 7, a 
two-prong approach is adopted. 
The first approach is to use of mRNA nanoparticles for tumor vaccination. The limiting 
factor in this approach has been poor transfection efficiencies of nanoparticle 
formulations. Nevertheless more efficient gene carriers have been developed in the past 
decade with some even made commercially available. In Chapter 3 (Specific Aim 1), a 
selected number of gene carriers that have been shown to be effective for other 
applications are evaluated for their ability to transfect primary DCs, and the best 
performing formulation is further evaluated in vivo for its transfection efficiency and 
expression kinetics. 
In Chapter 4 (Specific Aim 2), therapeutic efficacy of intranasal mRNA tumor vaccination 
is evaluated. The intranasal route of delivery is non-invasive and is amenable for 
repeated administrations. However, intranasal mRNA vaccination (with naked mRNA) 
has not been shown to induce anti-tumor immunity. Chapter 4 shows, for the first time, 
that intranasally administered mRNA can induce anti-tumor immunity in nanoparticle but 
not naked format. 
In Chapter 5, whole blood cells are evaluated as alternative cell based mRNA carriers. 
The rationale for choosing whole blood cells as the alternative cell source will be 
elaborated in later sections. In this Chapter, whole blood cells is evaluated for their ability 
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to encapsulate intact and functional mRNA, and for the induction of therapeutic anti-
tumor immunity against tyrosinase related 2 (TRP-2) in a melanoma immunotherapy 
model. 
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Figure 7. Overview of thesis objectives  
This thesis presents two mRNA delivery strategies that obviate extensive cell culture and manipulation needed for mRNA tumor 
vaccination. 
A. Compare transfection efficiency and kinetics of mRNA delivered in naked and nanoparticle formats.  
B. Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.  
C. Whole blood cells loaded with mRNA as an anti-tumor vaccine. 
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3 Transfection efficiency and transgene expression kinetics of 
mRNA delivered in naked and nanoparticle formats.  
3.1 Introduction 
 
The development of mRNA therapeutics received a significant boost following studies 
that demonstrated dendritic cells (DCs) pulsed with mRNA in vitro could become potent 
antigen-presenting cells in vivo1. Various delivery methods were explored to ascertain 
the most efficient method to transfect DCs with mRNA 8 and electroporation emerged as 
the preferred method. Ex vivo approaches to vaccination using autologous blood-derived 
DCs electroporated with tumor mRNA were developed and translated into clinical studies 
in patients with cancer 117. Nevertheless, nanoparticle-mediated delivery of mRNA to 
DCs warrants attention because of its potential advantages, the most important of which 
is the possibility of direct in vivo administration of mRNA vaccines without ex vivo 
manipulation of DCs. Encapsulation of mRNA in nanoparticles can also protect the 
mRNA from nuclease degradation, facilitate uptake, promote endosome escape, and 
provide conjugation sites to attach DC-specific receptor ligands for targeted delivery. An 
alternative that has been extensively investigated is in vivo administration of naked 
mRNA, which has been shown feasible to engender immune responses. Structural 
modifications such as length of poly-A tail 118, modified cap analogues 119, and 
pseudouridine substitution 48 as well as the use of Ringer’s Lactate (RL) 120 have 
enhanced naked mRNA transfection efficiency in vivo.  
As a rapidly emerging class of nucleic acid therapeutics, there are key benefits in using 
mRNA over plasmid DNA for vaccine or therapeutic applications. First, mRNA contains 
no viral promoters (e.g. CMV) and bacterial sequences that can cause toxicity. Second, 
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mRNA does not integrate into host genome, which may lead to deleterious mutation 121. 
Third, gene expression via mRNA is relatively transient and therefore safer to use 
compared to DNA. Last but not least, as mRNA does not need to cross the nuclear 
envelop, it increase the chances of successfully transfecting quiescent cells such as 
DCs. Indeed, mRNA can mediate a higher level of protein expression in vivo compared 
to DNA over shorter durations 120. Most recently, encouraging in vivo transfection 
mediated by naked mRNA has been reported where calcium-containing buffers such as 
Hank’s Balanced Salt Solution or Ringer’s Lactate are used in the injection 19. 
mRNA delivery to DCs using nanoparticles has also been recently explored. Su et al. 88 
adsorbed GFP-encoding mRNA to a pegylated and lipid-coated cationic core to obtain a 
30% transfection efficiency on DC2.4 cells in vitro, and achieved in vivo gene expression 
via intranasal administration. Perche et al. 40 encapsulated GFP mRNA into 
mannosylated lipopolyplexes and achieved approximately 60% transfection efficiency on 
DC2.4 cells in vitro. They also observed anti-tumor effects when mice were vaccinated 
intravenously with lipopolyplexes encapsulating the antigen mRNA. Intuitively, mRNA 
encapsulated in nanoparticles should mediate higher transfection efficiencies in vivo, but 
given the encouraging data reported on naked mRNA transfections, it becomes 
necessary to evaluate and compare transfection efficiency of gene carrier-mediated 
mRNA with naked mRNA delivery in vivo. In this paper, we hypothesize that mRNA 
delivered in nanoparticle format can be, in some ways, more efficient than naked mRNA. 
Using a commercially available mRNA transfection reagent, we show that it is possible to 
formulate stable mRNA nanoparticles in small volumes compatible with in vivo 
administration. We then evaluate and compare transfection efficiencies and transgene 
expression kinetics of these mRNA formulations (p/mRNA) with naked mRNA (n/mRNA) 
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dilutions of mouse serum but remained stable for at least 80 min with an average 
diameter below 350 nm, a size that remained conducive for endocytosis (Figure 8A). 
GFP mRNA nanoparticles were highly efficient in vitro. DC2.4 cells were transfected with 
a transfection efficiency >97%. JAWS II cells, which were morphologically more 
consistent with primary mouse DCs, were transfected reproducibly with at least 80% 
GFP+ efficiency. The transfection efficiencies of primary mouse and human DCs were 
>60% and >50% respectively (Figure 8B). These transfection efficiencies, to the best of 
our knowledge, were the highest in literature for mRNA nanoparticle delivery to DCs in 
vitro. Naked mRNA, however, failed to transfect any of the DC lines (Figure 8B).  
In vitro transgene expression kinetics on DC cell lines with mRNA nanoparticles were 
consistent with other cell types reported in literature 44. We also observed similar kinetics 
in primary mouse and human DCs (Figure 8C and 8D). Mouse DCs expressed luciferase 
within the first hour of transfection, much earlier than the typical 2-4 hour incubation time 
used for in vitro transfection. Transgene expression peaked rapidly at 5-hour post-
transfection and interestingly tapered off in a bi-phasic manner: a rapid and almost 
symmetrical drop in expression at the 9-hour time-point followed by a more gradual 
decrease that extended beyond 15-hr post-transfection. The trend in primary human DCs 
was similar although expression rose more gradually to peak at 7-hour post-transfection.
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Figure  8. Transfection efficiency of nanoparticle mRNA and naked mRNA in vitro. 
 
(A)  Aggregation kinetics of p/mLuc in 0-100% mouse serum.  
(B)  In vitro p/mGFP and n/mGFP transfection of primary DCs and DC cell lines.  
(C)  and (D) In vitro p/mLuc transgene expression kinetics of primary human peripheral blood 
monocyte-derived DCs and primary mouse bone marrow precursor-derived DCs respectively 
(‘X’ represents background luminescence). Cells seeded on the same 96-well plate were 
transfected at various time points with 0.4 g mLuc (n=5) and assayed after 15 hours. 
Results were averages of 3 independent experiments. 
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Figure 9. In vivo transfection efficiency of nanoparticle mRNA and naked mRNA 
administered intranasally. 
(A) Bioluminescence in C57BL/6 mice transfected intranasally with 4 g of p/mLuc and n/mLuc 
over a 24 hour time period.  NTC-: Non Transfected Control, no luciferin injected; NTC+: Non 
Transfected Control, luciferin injected; p/mOVA: mOVA nanoparticle  
(B) Representative set of IVIS images of nasally transfected mice 4 h post-intranasal delivery: (i) 
p/mLuc (ii) n/mLuc in NaAc Buffer (iii) n/mLuc in Ringer’s Lactate. Fifth mouse in panels (i) to 
(iii) is NTC+. *** p<0.0001 compared to p/mOVA, NTC- and NTC+ based on one-way anova 
(all 15 groups) followed by bonferroni multiple comparison test. * p<0.05 based on two tailed 
student’s t-test. 
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Figure 10. Evaluating in vivo transfection efficiency of nanoparticle mRNA and naked 
mRNA administered intravenously. 
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(A) Bioluminescence signal in BALB/c mice intravenously administered with 26 g of p/mLuc and ・
m/Luc.  
(B) IVIS images of mice transfected in (A) at 4 and 8 h time points with respective color scales. 
p/mOVA: mOVA nanoparticle NTC-: Non Transfected Control, luciferin not injected; NTC+: 
Non Transfected Control, luciferin injected. *** p<0.0001 compared to n/mLuc, p/mOVA, NTC- 
and NTC+ based one-way anova (all 8 groups) followed by bonferroni multiple comparison 
test. 
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Figure 11. Evaluation of in vivo bioluminescence after subcutaneous injection of mRNA 
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(A) In vivo bioluminescence in C57BL/6 mice transfected subcutaneously at the base of the ear 
pinna (SubQ-EP) with p/mLuc and n/Luc (in NaAc and RL) from 4-36 hours.  
(B) In vivo bioluminescence in C57BL/6 mice transfected subcutaneously at the base of tail 
(SubQ-BOT) with p/mLuc and n/Luc (in NaAc and RL) from 4-144 hours. pH of p/mLuc and 
NaAc buffer was adjusted to 7.4 with 1M Hepes, while pH of Ringer’s Lactate was kept at 
its native value of 5.5. (C, D, E)  
Representative IVIS images of transfected mice ear-pinnae (C) and base of tail (D) and (E) 
base of tail 4h post injection. *, **, ***: p<0.05, 0.005, 0.001 respectively based on two-tailed 
Student’s t-test (p/mLuc vs p/mOVA, n/mLuc vs NTC+). Detailed statistical analysis of (A) 
reported in Supplementary Figure 2. 
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Figure 12. Effect of RNase inhibitor and pH on mRNA transfection. 
 
(A) Effect of RNAse inhibitor on n/mLuc transfection at SubQ-EP. C57BL/6 mice were transfected with n/Luc +/- RNAse 
inhibitor (1unit/l) at SubQ-EP. Bioluminescence was assayed at 8, 12, and 24 h.   
(B) Effect of pH on n/mLuc transfection. C57BL/6 mice were transfected with n/Luc dissolved in NaAc (pH 5 or 7.4) and 
Ringer’s Lactate (pH 5.5 or 7.4). pH was adjusted with 1M Hepes. Bioluminescence was assayed at 4 h post injection. p 
values were calculated using two-tailed student’s t-test. 
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Figure 13. Regression analysis of luciferase expression kinetics in vivo. 
Representative curves from each site/format were shown above.  Additional regression curves were shown in Supplementary Figure 1.
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Table 3. Apparent in vivo half-life of luciferase protein expressed from mRNA 
 
Apparent Luciferase Half-Lives Expressed From mRNA 
Administration Site Delivery Format/Buffer Decay Constant Apparent Half-life/h 
Intranasal p/mLuc Exp 1 0.044 15.8 
Intranasal p/mLuc Exp 2 0.054 12.8 
Intranasal p/mLuc Exp 3 0.053 13.1 
SubQ-Base of tail p/mLuc NaAc 0.056 12.4 
SubQ-Ear Pinnae p/mLuc NaAc Exp 1 0.051 13.6 
SubQ-Ear Pinnae p/mLuc NaAc Exp 2 0.042 16.5 
Intravenous p/mLuc NaAc 0.510 1.4 
SubQ-Base of tail n/mLuc NaAc 0.036 19.3 
SubQ-Base of tail n/mLuc RL 0.039 17.8 
SubQ-Ear Pinnae n/mLuc NaAc Exp 1 0.098 7.1 
SubQ-Ear Pinnae n/mLuc NaAc Exp 2 0.092 7.5 
SubQ-Ear Pinnae n/mLuc RL Exp 1 0.129 5.4 
SubQ-Ear Pinnae n/mLuc RL Exp 2 0.138 5.0 
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3.4 Discussion 
 
Reports on nanoparticle-mediated delivery of mRNA, particularly in vivo, are relatively 
scarce compared to DNA delivery despite the advantages of obviating nuclear entry, 
avoiding insertional mutagenesis and more rapid gene expression. The transient and 
non-integrating nature of mRNA transfection is well suited for genetic vaccination. In this 
study, we first evaluated a number of mRNA nanoparticle formulations against dendritic 
cells with respect to their transfection efficiency, cytotoxicity, and colloidal stability at high 
concentration. The last parameter is important because it will allow us to vaccinate at a 
high dose in small injection volume. Of all gene carriers screened (Supplementary Figure 
3), which include lipofectamine, chitosan, PEI (25kda), polyamidoamine (CBA-ABOL) 123 
and lipopolyplexes of DOTAP/Chol and DOTAP/DOPE/Chol, Stemfect® produced the 
best results. In DC2.4 cell line, Stemfect attained a transfection efficiency of 97% (GFP+ 
population) compared to 60% by Perche et al. 40, 30% by Su et al.88 and 50% by Cheng 
et al. 94. There has not been any report on mRNA nanoparticle transfection of primary 
DCs, and we find that mRNA nanoparticles formulated using Stemfect transfect primary 
human and mouse DCs at transfection efficiencies of 52% and 64% (GFP+ cells) 
respectively. Our study provides encouraging direct evidence to proof the concept that it 
is possible to transfect primary DCs efficiently using mRNA nanoparticles. With the 
exception of one study reported by Perche et al. 40, mRNA vaccination has relied on the 
application of naked mRNA. In this study, we systematically compare the performance of 
mRNA nanoparticles formulated using Stemfect (p/mLuc) versus naked mRNA (n/mLuc) 
in intranasal, intravenous, or subcutaneous administrations. While p/mLuc outperforms 
n/mLuc in both intranasal and intravenous delivery, n/mLuc produces higher and more 
sustained transgene expression in subcutaneous injection. Since the intranasal and 
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intravenous routes target directly the Nasal Associated Lymphoid Tissues (NALT) and 
the spleen respectively, this study indicates the utility of nanoparticle-mediated mRNA 
for vaccination.  
Aside from targeting NALT, nasal administration of vaccine is popular due to its non-
invasive nature. We show that p/mLuc (4g dose) consistently achieves gene expression 
in the nasal cavity with an average radiance of 9x103 p/sec/cm2/sr at 4-hr post-delivery, 
whereas n/mLuc only produces background level at all time-points. Compared to the only 
other study that reported intranasal mRNA nanoparticle transfection (4g dose) 88 , this is 
the highest in vivo transfection efficiency we have observed. Within the n/mLuc groups, 
we are only able to detect bioluminescence from n/Luc (RL group) at 4th hour time point. 
Despite being transient, our finding highlights a significant contrast with naked pDNA, 
which does not transfect the nasal mucosa124. As the residence time of n/mLuc and 
p/mLuc in the nasal cavity is similar (Supplementary Figure 4), higher transfection 
efficiency of p/mLuc is unlikely due to better mucoadhesion. Furthermore, since RL is 
known to improve naked mRNA transfections via enhanced cellular uptake 120, we can 
reasonably infer that n/mLuc transfects poorly due to RNAse present in the nasal 
tissues. In our study, we also consistently detect bioluminescence from nasal cavities of 
non-transfected mice that are injected with luciferin (NTC+, Figure 9A) compared to 
those without luciferin (NTC-, Figure 9A). The difference, in photons/sec/cm2/sr, between 
NTC+ and NTC- is about one order of magnitude (Figure 9A). This appears to be unique 
to intranasal site as no such differences are observed in the spleen, ear pinna and base-
of-tail.  
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In contrast with other transfected sites, luciferase expression is most short-lived when 
delivered via intravenous route, which coincidentally targets the spleen. The near 
spleen-specific transfection is likely due to the unique properties of the gene carrier, 
which is closely related to a class of lipidoid previous reported for siRNA delivery 125. We 
also speculate that the colloidal stability of the nanoparticles in mouse serum promotes 
biodistribution to the spleen. In a preliminary experiment where we formulated p/mLuc 
with an un-optimized protocol that led to aggregation, transfection in the liver is also 
observed (Supplementary Figure 5). In Figure 10, where p/mLuc are formulated with an 
optimized protocol, moderate levels of transfection in the liver can still be observed in 2/6 
mice. Bulk mixing, the method used to formulate p/mLuc nanoparticles for this study, 
produces mRNA nanoparticles that are heterogeneous in size, surface charge, and likely 
composition. Recent literature has shown that a more controlled self-assembly of 
lipoplexes and polyplexes may lead to better performance with respect to colloidal 
stability, transfection efficiency, and even cytotoxicity59, 126, 127. These observations 
suggest that a more controlled formulation of the mRNA nanoparticles may improve and 
better predict in vivo performance. 
The significantly shorter half-life of luciferase at the spleen may be attributed to 
transfection of antigen presenting cells, which are very efficient in breaking down 
endogenous protein and presenting them on MHC complexes. In our hands, 
intravenously administered p/mRNA has an apparent half-life of 1.4 hours (R2=0.9984, 
N=6) and becomes undetectable at 24 hours. Unlike the subcutaneous or intranasal 
sites, the spleen is found under several layers of tissues and would have a higher 
threshold of detection, which may have contributed to a shorter apparent half-life as 
weaker luminescence at later time-points may not be detected.  
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Subcutaneous transfection with naked mRNA is well studied, but direct 
comparison with mRNA polyplexes or lipoplexes has not been reported.  In this study, 
we reproduced published data where n/mLuc transfection is enhanced by RL at SubQ-
EP by an order of magnitude 120. We also observe n/mLuc outperforming p/mLuc, not 
unlike pDNA transfection where naked DNA is often superior, if not equal, to polyplexes 
in intramuscular or subcutaneous transfection 128, 129.  Since the predominant cell types 
transfected by naked m/Luc at the ear-pinnae would be MHC-II negative such as muscle 
cells, fibroblasts and keratinocytes 120, we speculate several reasons for this observation: 
First, the majority of cells that take up and express mRNA could have been muscle cells, 
which are well known to be more efficiently transfected by naked nucleic acid. Second, 
uptake mechanisms for n/RNA and p/mRNA are different with the former significantly 
more efficient than the latter. Indeed naked mRNA uptake is facilitated by nucleic acid 
specific receptors 120, while nanoparticles uptake may have to depend on other non-
specific endocytic mechanisms, which may be directed into various degradative 
pathways. In this study we include an additional SubQ site at the base-of-tail, which not 
only is a favorable site for lymphatic drainage (5% Evans Blue injected subcutaneously 
at base-of-tail labels the inguinal lymph node within 30min 77), but also serves as an 
additional control to ear pinna site. We find consistent trends of higher transfection 
efficiency by n/mLuc over p/mLuc at both ear pinna and base-of-tail sites, indicating that 
SubQ may not be an ideal vaccination site for p/mLuc.  
An interesting finding from our study is that in vivo luciferase levels decay exponentially 
in a consistent manner regardless of format or site of administration. Hence apparent in 
vivo half-lives of luciferase protein expressed from mRNA, at given doses used in this 
study, can be computed. We noted earlier that apparent half-lives found between BOT 
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and EP sites are different for subcutaneous n/mLuc transfection. This can be attributed 
to the difference in cell type subdistribution at both sites as the BOT site is significantly 
more muscular than ear pinnae. Our reasoning is also supported by Figure4, where 
transfection enhancement by RL is much smaller at BOT (Figure 11B) compared to that 
at EP (Figure 11A). Cells found in the former respond more favorably to naked mRNA, 
reducing the need of RL for enhancement. Due to a different cellular makeup, 
intracellular stability of mLuc and/or luciferase protein consequently varies between both 
sites. 
Luciferase expression can be further extrapolated towards background levels to predict 
duration of gene expression. For SubQ-EP, detectable expression of both n/mLuc and 
p/mLuc can be extrapolated to 2-3 days, which is consistent with n/mLuc data from 
Probst et al. (3 days) 120. As one of the attractions of mRNA delivery is its transient 
nature, our data further support the idea that mRNA gene expression can be predictable 
and potentially controllable. This will help accelerate the translation of mRNA 
therapeutics into clinics.  
3.5 Conclusion 
 
In vitro and in vivo transfection efficiency and transgene expression kinetics of mRNA in 
naked and nanoparticle format are evaluated. We show that primary DCs can be 
efficiently transfected with mRNA nanoparticles with gene expression decaying in a 
biphasic manner. mRNA nanoparticles are also efficient in vivo when administered 
intranasally and intravenously, while naked mRNA dissolved in Ringer’s Lactate is the 
most efficient at subcutaneous sites (ear pinna and base-of-tail). Gene expression at all 
sites decays in consistent exponential trends, which may render mRNA gene therapy not 
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only safe but also predictable. This study shows that mRNA therapeutics adds to the 
armamentarium of biologics that can impact genetic medicine and warrants further 
research.  
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4 Intranasal vaccination with mRNA nanoparticles induces 
prophylactic and therapeutic anti-tumor immunity 
4.1 Introduction  
 
Tumor vaccination employing mRNA transfected dendritic cells (DCs) has been shown to 
be an effective strategy for treatment of cancer130-135. Promising results emerging from 
recent clinical trials3, 15, 136 supports the notion that this is a strategy that can be 
translated to humans and is amenable to commercialization. However, this process 
involves harvesting cells from patients via leukapheresis, generating DCs in vitro from 
adherent monocytes, loading them with mRNA, maturing them in vitro and re-injecting 
these mRNA-loaded DCs back into the patient. This is a cost, labor and resource 
intensive procedure. Because of these reasons, researchers have explored alternative 
cell-based approaches34, 35, as well as direct in vivo injection of mRNA in naked19, 36 and 
nanoparticle formats37-42. However, due to rapid degradation of naked mRNA in vivo, 
direct injection of mRNA is effective only when it is injected directly into lymph nodes19, 36. 
Intranodal injection is a highly invasive procedure in mice and hence not amenable for 
repeated administrations. Moreover, although intranodal injection is performed using 
ultrasound-guidance in humans, it remains a technically challenging procedure that 
requires surgical expertise. While this approach is an improvement over the existing ex 
vivo DC-based approach, scale-up remains a significant challenge thus hindering its 
broad application.  
A strategy that overcomes this problem is encapsulating mRNA in nanoparticles, which 
not only protects mRNA from nuclease degradation, but also facilitates its uptake by cells 
and endosome escape within cells leading to enhanced delivery efficiencies. This 
approach may obviate the need for intranodal administration, while still permitting direct 
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in vivo application of an off-the-shelf mRNA vaccine formulation via conventional routes 
of administration. Indeed, mRNA nanoparticle delivery has attracted interest from many 
research groups in recent years40, 44, 107, 137, 138. In addition, therapeutic efficacy of mRNA 
encapsulated in nanoparticles for tumor vaccination has also been recently 
demonstrated39, 40. Notably, tail vein and subcutaneous injections are the only routes 
evaluated in all of these studies. We have previously reported that primary DCs can be 
efficiently transfected by mRNA encapsulated in nanoparticles in vitro. These particles 
are about 180nm and 300nm in hydrodynamic diameter and have zeta potentials of 
+40mV/-12mV in water and 10% FBS supplemented media, respectively139. In the same 
study, we determined that luciferase expression mediated by nasally administered 
mRNA nanoparticles last for about 24 hours compared to naked mRNA, which is 
detectable only up to 4 hours post-administration139. The bioavailability of transgene 
product is clearly superior to nasally instilled soluble protein antigens, where >85% of the 
soluble antigen is cleared from the nasal site within 6 hours140. 
In this study, we hypothesize that nasal vaccination could be an effective strategy for 
mRNA tumor vaccination. Intranasal route of immunization is desirable because of its 
non-invasive nature, amenability for repeated administration and is associated with high 
patient compliance. It has been previously reported that intranasal immunization with 
naked mRNA can induce a moderate level of protection against tuberculosis in mice141. 
We reason that significantly higher nasal transfection efficiencies mediated by mRNA 
nanoparticles could translate to the induction of anti-tumor immunity. In addition, a 
previous study has reported that intranasal tumor vaccination with soluble OVA peptides 
can induce robust anti-tumor immunity142. Therefore we reason that the prolonged 
presence of antigen at the nasal site where the Nasal-Associated Lymphoid Tissues 
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(NALT) are located79 could translate to enhanced immune responses. Last but not least, 
we observe that nasally administered nanoparticles are taken up by CD11chigh cells 
isolated from NALT (Supplementary Figure 8), indicating that this route of administration 
could be used to directly target DCs. 
Based on above rationale, we set up an immunization scheme to investigate the 
therapeutic efficacy (Figure 14) of chicken ovalbumin (OVA) encoding mRNA 
nanoparticle vaccination in prophylactic and therapeutic immunotherapy models with 
E.G7-OVA tumor cells. The immunization schemes are based on published prime-boost 
protocol that entails weekly nasal administration for three weeks143 (prophylactic) and 
four injections every other day36 (therapeutic). Because we use cholera toxin (CT) as an 
adjuvant, there is a possibility that tumor immunity is induced by CT and not the OVA 
mRNA nanoparticle. To rule out this possibility, we immunize mice with green fluorescent 
protein (GFP) mRNA nanoparticles as controls. 
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immunized mice, specific growth rates did not progress at early time points, and this 
translated into the observed growth delay (Figure 16c). Amongst the six tumor-bearing 
mice within the mOVA-NP group (two were tumor free), three showed negligible growth 
during the first 48 hours. Hence, we concluded that intranasal vaccination with mRNA 
encapsulated in nanoparticle format could also be effective for therapeutic tumor 
vaccination. 
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Figure 17. Induction of antigen-specific T cells following intranasal immunization with OVA 
mRNA nanoparticles. 
a) OVA-specific splenic CD8+ T cells stained with H2-Kb OVA tetramers. Groups were mOVA-NP: 
mice immunized with OVA mRNA nanoparticles, mGFP-NP: mice immunized with GFP mRNA 
nanoparticles, mOVA-N: mice immunized with naked OVA mRNA. Results were averaged from 2 
independent experiments. Statistical significance comparing two groups was done using paired 
two-tailed Student’s t test. ***p<0.001. Representative flow plots of b) isotype and c) H2-Kb OVA 
tetramers, both from mOVA-NP group (prophylactic model).  
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4.4 Discussion 
 
In this proof-of-concept study, we demonstrate for the first time that intranasally 
administered mRNA encoding a tumor antigen can induce tumor immunity for the 
treatment of cancer. Our hypothesis is based on higher nasal transfection efficiencies 
and longer transgene expression kinetics achieved by mRNA nanoparticles as compared 
to mRNA delivered in the naked format. Mice treated with OVA mRNA encapsulated in 
nanoparticle, demonstrated delay in both tumor onset and overall survival compared to 
controls in prophylactic and therapeutic E.G7-OVA tumor model.  
The overall survival and tumor onset of mOVA-NP group in the prophylactic model are 
clearly superior to mOVA-N group (Figure 15, Table 4). However, in therapeutic model 
the improvement is less distinct. When tumor growth kinetics between mOVA-N and 
mGFP-NP groups are compared, we observe that growth curves in the mOVA-N group 
completely overlapped with mGFP-NP group in the prophylactic model (Figure 16c), but 
a minor difference is seen in the therapeutic model (Figure 16c). This suggests that 
naked mRNA immunization had a slight effect in the latter. However, the difference in the 
latter is not statistically significant. The reason for this could be that the robust innate 
immune response mediated by cholera toxin facilitated the induction of an adaptive 
immune response following naked mRNA immunization in the nasal cavity. This 
corroborates data from another study demonstrating that nasally administered naked 
mRNA induces immune responses for the treatment of tuberculosis141. 
In the therapeutic setting, we also observe that nascent tumors in every tumor bearing 
mouse treated with OVA mRNA nanoparticles do not proliferate aggressively. This may 
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be attributed to immune response generated from intranasal immunization. Since tumor 
cells can escape immune surveillance146-149 through immune suppression150, 151, altered 
expression of MHC class I152, 153, as well as generation of immune escape tumor 
variants154, specific growth rates eventually caught up with that of control groups (Figure 
16c and 16d). Lastly, through tetramer staining analysis we demonstrate that to induce 
anti-tumor immunity via intranasal route, it is necessary that mRNA is delivered in a 
nanoparticle.  
Because intranasal delivery is a desirable route for vaccination, it has been extensively 
studied in the past decade. In particular, micro- and nano-particle delivery systems that 
encapsulate protein antigens or DNA that encode for antigens have been evaluated. 
However, the focus of intranasal vaccination has often been on the treatment of 
infectious diseases124, 143, 155-160. Nonetheless, a recent study has demonstrated that 
nanoparticles composed of modified -polyglutamic acid (-PGA) encapsulating full 
length OVA protein instilled intranasally induced anti-tumor immunity against 
melanoma83. In addition, a recent study also investigated the use of mannosylated 
chitosan-DNA (CS-DNA) nanoparticle vaccine for the prophylactic treatment of prostate 
carcinoma via the intranasal route. Anti-tumor response was only observed in the group 
that received targeted CS-DNA nanoparticles, but not in the group that received non-
targeted nanoparticles. However, the therapeutic efficacy of the targeted CS-DNA 
nanoparticles was relatively similar to intramuscular vaccination using soluble antigen161.   
Our results contribute to a relatively small number of studies published on mRNA 
nanoparticle mediated tumor vaccination where overall survival is one of the endpoints37, 
39, 40, 42. In addition, results from our current study also support the concept of nasal 
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vaccination as an option for mRNA cancer immunotherapy. However, the therapeutic 
efficacy achieved in our current study is relatively moderate and we are uncertain how it 
compares with other administration routes or other established methods of mRNA 
vaccination. Therefore, future studies will focus on comparing this approach with other 
RNA-based methods and optimization of the current protocol to improve therapeutic 
efficacy.  
For mRNA tumor vaccination to be clinically useful and broadly applicable, it is important 
that it is an off-the-shelf therapy that can be administered directly in vivo. In this report, 
we show that a convenient, non-invasive method can be used for direct in vivo 
administration of mRNA encoding tumor antigen, however it has to be delivered in 
nanoparticle format. This is an attractive prospect for the broad application of mRNA 
vaccines and reveals a major gap in the development of mRNA gene carriers for cancer 
immunotherapy.  
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5 Whole blood cells loaded with messenger RNA as an anti-tumor 
vaccine 
5.1 Introduction 
 
In vitro transcribed mRNA is an immunogenic and programmable molecule1 that 
embodies key advantages as an antigen-encoding gene for cell-based immunotherapy. 
For example, the use of mRNA obviates prior knowledge of patient’s Human Leukocyte 
Antigen (HLA) type, a pre-requisite for class I peptide epitope-based approaches. mRNA 
is also expressed more efficiently than DNA because it does not need to cross the 
nuclear envelope. To date a number of methods aimed at using mRNA to stimulate 
immune responses have been studied. They include transfection of antigen-presenting 
cells (APCs) ex vivo with mRNAs encoding defined antigens 1, 13 or with total mRNA 
repertoire from tumor cells, 162 as well as direct injection of mRNA in vivo. 19, 36, 163 
Dendritic cells (DCs) are the most common APCs that have been loaded with antigen-
encoding mRNA, as well as antigens in a variety of formats. A major disadvantage of 
using transfected DCs as a vaccine is that the process of harvesting, culturing and 
loading DCs is time- and resource-intensive. It requires that patients undergo at least 
one 4-hour leukapheresis procedure, followed by separation of the peripheral blood 
mononuclear cells (PBMCs), from which the monocytes are isolated and cultured for a 
week in a defined medium with cytokines. The resulting DCs are typically matured before 
or after being loaded with mRNA and frozen for storage. Aliquots are subsequently 
thawed prior to administration to patients. In efforts to circumvent these somewhat 
cumbersome procedures, many groups have investigated direct injection of antigen-
encoding mRNA. 19, 36, 163 While this has the advantage of simplicity, there are still 
manufacturing steps that require time, specialized resources and often proprietary 
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formulations. This is particularly true in the case of mRNA, which has distinct advantages 
as a source of antigen but must be protected in vivo from nucleases. Recently, a study 
demonstrated that DC vaccination is significantly less effective in antigen-presenting cell 
(APC)-deficient mice 116 compared to wild-type mice. The authors concluded that ex vivo 
transferred DCs function primarily as vehicles for transferring antigens to endogenous 
APCs, which are responsible for the subsequent activation of T cells.116 This raises the 
possibility of using alternative cell types for mRNA cell based vaccination. In the search 
of such an alternative, we find that the blood is an attractive cell source because it is 
biocompatible, quickly available in large quantities and contains a variety of immune 
cells. Notably, erythrocytes loaded with protein tumor antigens have been extensively 
studied as vaccine carriers.164-169 In addition, peripheral blood monocytic cells loaded 
with tumor antigens also proved to be an effective tumor vaccine, e.g. Provenge 4 which 
is FDA approved in 2011. In both approaches, however, it is necessary to subject blood 
cells freshly derived from the body to manipulation164-169 and cell culture170 before arriving 
at the final vaccine preparation. This increases complexity and cost of treatment, 
dampening the prospect of broad application of cell-based vaccines.5, 6 We hypothesize 
that cell-based vaccination can be achieved with a more simplified and direct approach 
by loading mRNA directly into whole blood cells immediately after isolation from the 
body.  We take advantage of the fact that blood is made up of a heterogeneous cell 
mixture that includes not only erythrocytes, but also leukocytes and reticulocytes. 
Notably, reticulocytes still retain the ability to translate mRNA into proteins.171 Hence, by 
loading mRNA into autologous whole blood cells,  mRNA may be delivered to 
endogenous host APCs via erythrocytes (naturally enriched in RNase-inhibitor172) in form 
of untranslated mRNA. Additionally, leukocytes and reticulocytes may deliver both 
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To quantify luciferase expression, cells were centrifuged, supernatant discarded, the cell 
pellet re-suspended in 50l of Glo Lysis buffer and transferred to a white opaque 
microplate. 75µl of Steady-Glo luciferase reagent was added, mixed using an orbital 
shaker and luminescence read with a microplate reader (FLUOstar Optima) equipped 
with a luminescence optic. 
5.2.10.1 RT-PCR  
RNeasy Plus (Qiagen) was used to isolate total RNA from non-electroporated blood, as 
well as blood electroporated with actin or TRP-2 RNA. Total RNA was used in a reverse 
transcription reaction primed with oligo dT and carried out with SMARTScribe reverse 
transcriptase (Clontech). One-tenth of the RT reaction was used in PCR with actin 
primers:  
5’-ATGGTGGGAATGGGTCAGAAGGAC-3’ and 5’-
CTCTTTGATGTCACGCACGATTTC-3’, or TRP-2 primers: 5’-
GCCATTGATTTCTCTCACCAAGG-3’ and  5’-GTCCAGTGTTCCGTCTGCTTTATC-3’. 
5.2.10.2 Fluorescence and confocal imaging 
Cells were washed and fixed by retaining 50% of the supernatant, while replacing the 
other half with fixing media (Opti-MEM containing 4% paraformaldehyde prepared 
immediately before use). This was repeated 4 times and cells were transferred into 96-
well microplates (BD), centrifuged (1000 rpm) and imaged at 40x magnification using a 
Nikon camera. For confocal microscopy, fixed cells were transferred to 96-well glass-
bottom plates (Greiner) previously coated for 1 hour with 100µg/ml poly-L-lysine, 
centrifuged (1000 rpm) and imaged immediately using an inverted oil immersion confocal 
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microscope (Zeiss LSM 510) at 100x magnification. In some instances, images were 
digitally magnified to 200x. 
5.2.10.3 In vivo biodistribution 
To evaluate in vivo biodistribution, each mouse received 109 naïve or mRNA-loaded 
blood cells injected via tail vein. Lungs, spleen, liver and kidneys were isolated 2 hours 
post injection, weighed and imaged immediately using IVIS Kinetics (Calipers, Excitation 
615-665nm; Emission 695-770nm).  
5.2.10.4 Cell marker Staining 
Cy5-labeled mRNA was loaded into whole blood cells as previously described. 109 
mRNA loaded whole blood cells were prepared for 10 staining aliquots in 20ml pre-
warmed complete Opti-MEM. Supernatant was discarded and erythrocytes were 
depleted by ammonium chloride lysis. Remaining cells were centrifuged and 
resuspended in 1ml PBS supplemented with 10% FBS. Cells were blocked with 25µl 
anti-mouse CD16/32 (Biolegend) for 15 minutes on ice. 100µl of cells were mixed with 
2.5µl of FITC/PE-labeled antibodies (and corresponding isotypes) for 45min on ice. Cells 
were washed, fixed with PBS containing 1% paraformaldehyde and immediately 
analyzed by flow cytometry (BD FACSCaliber). Data was subsequently analyzed with 
WINMDI 2.9 freeware. 
5.2.10.5 Biological states 
Prior to the below mentioned assays, cell stock containing 200µl of electroporated cells 
recovered in 2ml of complete Opti-MEM were incubated at 37oC and 5% CO2 for 2 hours. 
Live assay and reactive oxygen species (ROS) measurement were performed using 
calcein-AM (Molecular Probes). Calcein-AM was diluted into 0.5ml of complete Opti-
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MEM to a final concentration of 1µM. 100µl from cell stock was then added, incubated at 
room temperature for 30 minutes and directly analyzed by flow cytometry. Live assay 
was quantified based on %FITCpositive cells while the ROS was quantified based on mean 
fluorescence intensity (MFI) of FITC.   
To assay for caspase 3 activities, 500µl of mRNA-loaded cells (EP+RNA) or negative 
control (No EP, handled in exactly the same way except without electroporation) were 
diluted with 150µl of Opti-MEM to a final volume of 650µl. Alternately, tert-
butylhydroperoxide (tBOOH, Sigma) was diluted into 100µl of Opti-MEM and 
immediately added to 500µl of naïve cells so that the final concentrations of tBOOH are 
0, 1.3 and 2.6mM respectively. These positive controls were treated with tBOOH for 
exactly 8 minutes in Opti-MEM at room temperature. After 8 minutes, 50µl of ME 
(55mM, Gibco) was added to quench the reaction and 50µl from each tube was 
immediately mixed with 75µl of Caspase 3/7-GLO (Promega), transferred into 96-well 
white opaque plates, incubated for 30 minutes at room temperature and analyzed for 
luminescence using a microplate reader (FLUOstar Optima). Data were recorded after 
luminescence stabilized and normalized against cell number. Cell number in each tube 
was determined by counting using a hemocytometer. 
To assay for phosphatidylserine exposure, 150µl from cell stock was aliquoted and 
supernatant was removed by centrifugation. 100µl of annexin V binding buffer was 
added followed by 5µl of PE (Biolegend) or Cy5 (Molecular Probes) labeled annexin V 
reagent. Cells were incubated for 15 minutes, diluted with 300µl of binding buffer and 
immediately analyzed by flow cytometry. 
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by both fluorescence and confocal microscopy (Figure 18B and Figure 18C). Using flow 
cytometry, we further determined, within the leukocyte population, that mRNA was 
loaded into MHC class II+ antigen-presenting cells, CD3+ T cells, CD11b+ monocytes, 
GR1+ granulocytes and CD45R+/B220+ murine plasmacytoid DCs (Figure 18D). 
Quantification of the fluorescently-labeled mRNA showed that about 300ng of RNA was 
loaded into 5x107 blood cells (Figure 19A), and amplification by RT-PCR of full length 
mRNA from mRNA-loaded blood cells (Figure 19B) indicated that untranslated mRNA 
remained stable within the cytoplasm of whole blood cells. 172 Luciferase expression 
detected in luciferase mRNA-loaded blood cells (Figure 19A) confirmed the bioactivity of 
the mRNA. Thus, intact and functional mRNA could be loaded into whole blood cells by 
electroporation. 
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Figure 18. Whole blood cells can be loaded with mRNA. 
A. Ungated 3D plot of Cy5-labeled GFP mRNA (Cy5-RNA) loaded into reticulocytes (TOintermediateFSClow), leukocytes (TOhighFSChigh), 
erythrocytes (TOlowFSClow) based on size (FSC) and presence of endogenous DNA/RNA (Thiazole Orange, TO).   
B. Fluorescence image of mRNA-loaded whole blood cells. GREEN: FITC-labeled GFP mRNA.   
C. Confocal images of mRNA encapsulated in erythrocytes, leukocytes and reticulocytes. RED: Cy5-labeled GFP mRNA loaded by 
electroporation, GREEN: Thiazole stain of cellular DNA/RNA .   
D. Loading efficiency of Cy5-labeled GFP mRNA into reticulocytes (TOintermediateFSClow), leukocytes (TOhighFSChigh), erythrocytes 
(TOlowFSClow), monocytes (CD11b), T cells (CD3), antigen presenting cells (MHC II), granulocytes (GR1) and murine plasmacytoid 
DCs (CD45R/B220). 
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Next we characterized the biological properties of whole blood cells two hours post-
electroporation. This time point was chosen because mRNA-loaded whole blood cells 
were typically administered into all mice by the second hour post-electroporation. We 
observed that mRNA-loaded blood cells remained viable (Figure 20A) based on the 
conversion of non-fluorescent calcein-AM to fluorescent calcein by intracellular 
esterases. We also found elevated levels of reactive oxygen species (ROS) in 
electroporated blood cells based on higher mean fluorescence intensity contributed by 
oxidized calcein-AM. Only those that were loaded with mRNA possessed higher levels of 
ROS (Figure 20B). ROS are pro-inflammatory and thereby a potentially favorable 
property for whole blood cell vaccines.177 Using annexin V staining, we observed that 
cells loaded with mRNA externalized phosphatidylserine (PS) compared to unloaded 
blood cells (Figure 20C, Supplementary Figure 9). Surface presentation of PS could be 
caused by scrambling of cell membranes lipids facilitated by pore formation during 
electroporation, 178 or it could indicate that the blood cells were apoptotic. To ascertain 
whether PS externalization was physically mediated, we tracked PS externalization 
immediately after electroporation and found that cells were stained positive for annexin V 
immediately after electroporation (Supplementary Figure 10). Surface PS also appeared 
to be irreversible, increasing slightly during recovery but dropping back to levels seen 
immediately after electroporation by 24 h (Supplementary Figure 10). We then analyzed 
mRNA-loaded whole blood cells for apoptosis based on caspase-3 activities 179-181 and 
found that they were comparable to naïve cells (Supplementary Figure 11). This 
indicated that surface PS presentation was not caspase-mediated and suggested that 
PS presentation might not be biologically mediated. Surface PS commonly known as 
“eat-me” signals displayed selectively on live mRNA-loaded cells presumably target 
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them to the mononuclear-phagocyte system for uptake. To summarize, we show that 
electroporation of whole blood cells results in mRNA electroinsertion and priming for 
antigen uptake in vivo 
Next we determined the biodistribution of mRNA-loaded whole blood cells following 
intravenous administration and found that RNA-loaded whole blood cells were distributed 
to multiple organs, including the APC-rich liver and spleen (Figure 20C). Additionally, 
mRNA-loaded blood cells, despite being relatively low in abundance (Figure 18A), 
efficiently co-localized with APCs in vitro (Supplementary Figure 12). This was consistent 
with prior reports on live erythrocytes that had phosphatidylserine artificially inserted in 
the cell membrane.182 Hence we confirmed that mRNA-loaded whole blood cells were 
distributed to the liver and spleen, where they could be targeted to antigen presenting 
cells. 
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Figure 19. Characterization of electroinserted mRNA, biological properties and biodistribution of mRNA-loaded whole blood cells.  
 
A. Mass of Cy5-labeled luciferase mRNA loaded in 107 whole blood cells (left axis) and luciferase expression per 107  whole blood 
cells normalized to 107 non-electroporated cells.  
B. RT-PCR analysis of RNA recovered from whole blood cells loaded with actin mRNA (“A”), TRP-2 mRNA (“T”) or nothing, 
respectively. Lane M is a 1 Kb DNA ladder (Invitrogen).  
C. Ungated 3D plot of cell viability based on conversion of calcein-AM to calcein in whole blood cells loaded with Cy5-labeled GFP 
mRNA.  
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Figure 20. Characterization of biological properties and biodistribution of mRNA-loaded whole blood cells. 
 
A. ROS levels in whole blood cells based on mean fluorescence intensity (MFI) of intracellular calcein183.   
B. Surface phosphatidylserine analysis by annexin V staining.   
C. IVIS image of biodistribution of whole blood cells loaded with Cy5-labeled GFP mRNA administered intravenously via tail 
vein 2 hours post administration. This experiment was repeated 2 times with n=3 and one experiment is depicted. Cells were 
assayed 2 hours post-electroporation. ** p<0.01, ***p<0.001 (One-way anova/bonferroni multiple comparison test) 
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Based on the data presented in Figures 18-20, we hypothesized that whole blood cells 
loaded with mRNA encoding antigen protein could induce antigen-specific immune 
responses. We first monitored induction of B cell responses by measuring the presence 
of antigen-specific serum IgG in mice immunized twice with ovalbumin (OVA) mRNA-
loaded blood cells. As shown in Figure 21A, OVA-specific serum IgG could be detected 
in immunized mice. To monitor induction of T cell responses, two groups of mice were 
immunized once with blood cells loaded with mRNA encoding either OVA or the murine 
melanoma antigen, tyrosinase-related protein 2 (TRP-2). Upon re-stimulation of splenic 
lymphocytes in vitro, we analyzed T cells for antigen-specific function by measuring IFN-
 secretion upon antigen re-encounter or lysis of target cells expressing antigen. Antigen-
specific IFN- secretion by OVA- or TRP-2-specific CD8+ and CD4+ T cells is shown in 
Figure 21B. T cells also showed antigen-specific reactivity by selectively lysing target 
cells that expressed the corresponding antigen (Figure 21C). Hence, we conclude that 
mRNA-loaded blood cells injected immediately after electroinsertion and without further 
manipulation can induce both humoral and cellular immune response. 
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Figure 21. Immunization with mRNA-loaded whole blood cells induces immune responses in vivo.  
 
A. Induction of OVA-specific antibody responses. Serum collected from naïve mice was used as the negative control. Statistical analysis 
was done using a student’s t test. **p<0.01, ***p<0.001 
B. Induction of antigen-specific IFN- secreting T cells in mice immunized with mRNA-loaded whole blood cells. Isolated CD4+ and CD8+ 
T cells were stimulated with EL4 cells previously transfected with either TRP-2 or OVA mRNA. After overnight incubation an IFN- ELISpot 
was performed. Statistical analysis was done using a student’s t test. **p<0.01, ***p<0.001 
C. Induction of antigen-specific cytotoxic T cells in mice immunized with mRNA-loaded whole blood cells. A europium-release CTL assay 
was performed 5-days post-stimulation. EL4 thymoma cells electroporated with antigen-encoding mRNA (TRP-2 or OVA) were used as 
targets to measure antigen-specific lysis. 
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We next evaluated the therapeutic efficacy of mRNA-loaded blood cells in the B16 
melanoma immunotherapy model. Mice were immunized one time 2 days post-tumor 
implantation with mRNA-loaded whole blood cells and as a positive control, TRP-2 
mRNA-loaded DCs (Figure 22A, 22B and 22C). Immunization with melanoma antigen 
TRP-2 mRNA-loaded whole blood cells delayed tumor onset (Figure 22A) and enhanced 
survival (Figure 22B) as compared to whole blood cells loaded with mouse actin mRNA. 
Moreover, there was no difference in tumor onset (p=0.57, Figure 22A), survival (p=0.33, 
Figure 22B) and average tumor diameter (p=0.97, Figure 22C) in mice immunized with 
TRP-2 mRNA-loaded whole blood cells and TRP-2 mRNA-loaded DCs. These results 
demonstrate that immunization with TRP-2 mRNA-loaded whole blood cells leads to an 
antitumor response that is comparable to TRP-2 mRNA-loaded DCs.  
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Figure  22. Immunization with mRNA-loaded whole blood cells is comparable to dendritic 
cell (DC) vaccination in the B16 melanoma immunotherapy model. 
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A. Delay in tumor onset in mice immunized with mRNA-loaded whole blood cells. Time to 
tumor onset was recorded based on the detection of palpable tumors (~4-5 mm 
diameter). Log-rank analysis (Mantel-Cox test) was used for statistical analysis: Blood 
cells+actin mRNA vs Blood cells+TRP-2 mRNA, p=0.0001; Blood cells+actin mRNA vs 
DCs+TRP-2 mRNA, p=0.0007; Blood cells+TRP-2 mRNA vs DCs+TRP-2 mRNA, 
p=0.52. Median time to tumor onset: Blood Cells+actin mRNA=18, Blood Cells+TRP-2 
mRNA=23, DCs+TRP-2 mRNA=24. 
B. Enhanced survival in mice immunized with mRNA-loaded whole blood cells. Survival 
was recorded based on tumor growth to 20 mm in diameter at which point mice were 
sacrificed. Log-rank analysis (Mantel-Cox test) was used for statistical analysis: Blood 
cells+actin mRNA vs Blood cells+TRP-2 mRNA, p=0.0001; Blood cells+actin mRNA vs 
DCs+TRP-2 mRNA, p=0.0001; Blood cells+TRP-2 mRNA vs DCs+TRP-2 mRNA, 
p=0.33. Median time to tumor onset: Blood Cells+actin mRNA=23.5, Blood Cells+TRP-
2 mRNA=31, DCs+TRP-2 mRNA=32. 
C. Induction of anti-tumor immunity is comparable in mice immunized with mRNA-loaded 
whole blood cells and DCs transfected with mRNA. Figure depicts tumor diameter in 
individual mice and average tumor diameter on day 22. The overall significance of the 
study as determined by Kruskal-Wallis (ANOVA) test is p=0.0002. The comparison 
between groups was done using the non-parametric Mann-Whitney test: Blood 
cells+actin mRNA vs Blood cells+TRP-2 mRNA, p<0.0001; Blood cells+actin mRNA vs 
DCs+TRP-2 mRNA, p=0.0002; Blood cells+TRP-2 mRNA vs DCs+TRP-2 mRNA, 
p=0.97. 
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5.4 Discussion 
 
This report provides proof-of-concept of a rapid and affordable cellular immunotherapy. 
Our approach is based on the hypothesis that immunization with mRNA-loaded whole 
blood cells will lead to an anti-tumor immune response. As this vaccine is designed to be 
an autologous cell product, it is unlikely to be toxic or be affected by blood types of the 
individuals. We have also not observed other visible side effects from this vaccine 
formulation in all our animal experiments.  
Our formulation is distinctly different from red blood cell vaccines. 164-169 Firstly, buffy coat 
cells (leukocytes) are not removed by Ficoll-Paque separation.165 As a result, mRNA is 
also loaded into leukocytes, which leads to the translation of the mRNA into protein 
(Figure 19A). Secondly, mRNA is loaded into whole blood cells by electroporation 
instead of hypotonic loading. The latter is not suitable because it requires prolonged 
incubation of labile mRNA with cells, which requires a RNAse-free environment. Thirdly, 
our formulation is rapidly distributed to the liver and spleen compared to most red blood 
cell vaccine which requires additional pretreatment to achieve opsinization 184. This rapid 
distribution could have been a consequence of cluster formation (Figure 18B and 18C) 
as well as the externalization of phosphatidylserine (PS) “eat-me” signals on the cell 
surface (Figure 20B).  
As important, immunization with mRNA-loaded whole blood cells leads to induction of 
immune responses. Notably, the dose applied in this study contains only about 150 
nanograms of mRNA (Figure 19A). Although nanogram quantities of mRNA 
encapsulated in nanoparticles using lipid-based gene carriers have been effective for 
erythropoietin delivery,137  tumor vaccination may require microgram quantities as 
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previously reported for intravenously administered mRNA-nanoparticle vaccine.114 It is 
also reasonable to assume that synthetic gene carriers will be more efficient than 
erythrocytes in transfecting APCs. As such, there is a very low chance for host APCs to 
be directly transfected by mRNA encapsulated inside erythrocytes.  Our results suggest 
that transfected leukocytes may be involved in the induction of immune response, 
especially since a variety of them are loaded with tumor antigen encoding mRNA. This 
speculation is consistent with predominant role of cell-based vaccines for transfering 
antigens to host APCs.116 Future studies will address the mechanism of immune 
response induction, which will allow us to further understand and optimize this vaccine 
formulation. 
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6 Conclusion 
A significant bottle neck to broad translation of mRNA cell based vaccination is the 
extensive cell manipulation and culture required to derive matured mRNA transfected 
DCs from autologous blood monocytes. This thesis presents two viable strategies that 
eliminates or significantly reduce these time- and resource- consuming processes. 
The first approach adopts a direct in vivo administration of mRNA. Due to a lack of a 
suitable mRNA carrier, therapeutic efficacy of directly injected mRNA has been shown 
only by intranodal injection of naked mRNA. Through screening of a selected number of 
gene carriers, an optimal formulation capable of transfecting primary dendritic cells 
efficiently is identified, demonstrating for the first time that primary dendritic cells can be 
efficiently transfected with mRNA encapsulated nanoparticles. The in vivo transfection 
efficiency and kinetics of mRNA nanoparticles are compared with naked mRNA, which is 
well characterized in vivo. 
Results of the above study suggest a possibility for intranasal route of mRNA tumor 
vaccination, a delivery strategy that has not been studied. We further show, in a follow 
up study, that mice intranasally immunized with mRNA encapsulated in nanoparticles 
delivering OVA as a model antigen develop anti-tumor immunity under both prophylactic 
and therapeutic settings. Anti-tumor immunity correlates with the development of antigen 
specific CD8+ T cells, and is observed only when mRNA is delivered in nanoparticles but 
not in naked format. Intranasal administration is a highly attractive delivery route due to 
its non-invasive nature and amenability for repeated administrations. Results from this 
thesis show the potential for a broad clinical translation of a non-invasive mRNA tumor 
125 
 
vaccine. The development of safe and efficient gene carriers as well as further 
optimization of intranasal mRNA tumor vaccination are warranted. 
The second approach explores the use of whole blood cells as alternative cell carriers of 
mRNA. The hypothesis is based on the fact that DC therapy relies heavily on 
endogenous DCs for anti-tumor immune response, suggesting alternative cell types may 
be equally effective. We show that intact and functional mRNA can be loaded into whole 
blood cells by electroporation. These cells engender properties such as high ROS and 
surface presentation of phosphatidylserine, which facilitates their uptake by endogenous 
antigen presenting cells. We show that mice immunized with mRNA-loaded whole blood 
develop both B and T cell antigen specific immune responses. And in a therapeutic 
melanoma immunotherapy model employing TRP-2 as the antigen, the overall survival 
of mice immunized with mRNA-loaded whole blood cells are comparable with 
intraperitoneally administered mRNA-transfect DCs. 
In conclusion, we have demonstrated proof-of-concept methods of mRNA delivery that 
obviate the time- and resourcing- demanding procedures currently needed for mRNA 
tumor vaccination. Studies presented in this thesis opens additional significant areas of 
research for future work. For intranasal mRNA tumor vaccination, the optimal adjuvant 
and vaccination schedule still needs to be optimized. The therapeutic efficacy of an 
optimized intranasal mRNA tumor vaccination procedure should also be compared with 
other delivery routes as well as the mRNA-transfected DCs to ascertain its potential for 
clinical translation. For mRNA-loaded whole blood cell vaccination, a few attempts were 
made to optimize this formulation and results were mixed. These mixed outcomes are a 
result of a lack of true understanding on the mechanism of immune modulation mediated 
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by mRNA-loaded whole blood cells. A major complexity comes from the fact that a wide 
variety of cell types are loaded with mRNA. Future work in this area will focus on the 
elucidating the mechanism of action by this highly simplified tumor vaccination approach 
so that an appropriate study can be designed to optimize it. In addition, this method of 
vaccination may in its present form by extended to other disease models such as 
influenza or tolerogenic immunotherapy. 
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7 Future directions 
An unexpected finding in Specific Aim 1 is that subcutaneous transfection with naked 
mRNA is more efficient and sustained compared to mRNA encapsulated in 
nanoparticles. Notably gene expression last for more than 3 to 7 days depending on 
specific subcutaneous locations. Protein expression from mRNA also decays with a first 
order kinetics regardless of route or format of delivery, rendering subcutaneous mRNA 
transfection a predictable event. These unique subcutaneous transfection properties of 
naked mRNA may be useful in wound healing and other skin injuries commonly 
encountered in plastic and reconstruction surgeries.  
We have previously shown, as a proof-of-concept, that freshly obtained whole blood cells 
can be loaded with mRNA and immediately re-injected back into the body as an anti-
tumor vaccine. The next logical step would be to optimize the vaccine formulation. To 
optimize mRNA-loaded whole blood cell vaccine, it is necessary to know the “relative 
contribution” of erythrocytes and leukocytes to antigen specific immune response. This is 
because unlike leukocytes, erythrocytes do not translate mRNA into protein. 
Consequently, immune modulation mediated by erythrocytes may be fundamentally 
different from leukocytes. This may lead to very different hypotheses on how tumor 
immunity was induced. The “relative contribution” approach may be used to first identify 
the cell type most implicated in the induction of antigen specific immune response. 
Based on this identified cell type, we will formulate testable hypotheses to probe a 
probable mechanism of action mRNA-loaded whole blood cells. The actual mechanism 
may be highly complicated and not practical to elucidate since the purpose is to optimize 
the therapeutic efficacy. 
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Going forward, this formulation may be further developed into a “point-of-care” vaccine 
technology. Whole blood obtained from the patient can be immediately infused into an 
integrated microfluidic platform where the erythrocytes and leukocytes are separated into 
different channels, followed by flow electroporation within each channel (electroporated 
with cell-type optimized parameters) leading to optimal loading of mRNA into 
erythrocytes and leukocytes, respectively. Cells exiting the chip may be injected directly 
into the patient without further manipulation.  
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Appendix 
 
Supplementary Figure 1. Regression analysis of additional transgene expression kinetics 
experiment 
 
 
Supplementary Figure 2. Detailed statistical analysis of data presented in Figure 11 
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Supplementary Figure 3. Gene carriers preliminarily screened for mRNA nanoparticle transfection 
on JAWS II cell line.  
A. CBA-ABOL, B. Lipofectamine, C. DOTAP (1,2-dioleoyl-3-trimethylammonium-propane), D. 
DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), E. Chitosan, F. PEI (25kda) 
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Supplementary Figure 4. 4 g of Cy-5 labeled mLuc was administered intranasally into 
Balb/c mice.  
Cy-5 fluorescence was monitored at indicated time points using IVIS Kinetics Imaging 
System. Results from 2 independent experiments (n=2/group) were normalized to 
respective non-transfected controls  (NTC) and plotted on the same graph. 
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Supplementary Figure 5. Bioluminescence in BALB/c mice intravenously administered with 
26 g of partially aggregated p/mLuc at 4 and 8-hour post injection. 
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Supplementary Figure 6. Zeta potential of mRNA nanoparticles applied in this study.  
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Supplementary Figure 7. Fluorescence microscope images of JAWS II cell transfected with 
nanoparticles co-encapsulating GFP and Cy5 labeled GFP mRNA. 
A. Bright field. B. Cy5-labeled mGFP. C. GFP expression. D. GFP/Cy5 merge. 
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Supplementary Figure 8. Evaluating in vivo  transfection efficiency of luciferase mRNA 
nanoparticle. 
a) C57Bl/6 mice were administered intranasally with 6g mRNA. From left: luciferase mRNA 
(mLuc-NP) nanoparticles, naked mLuc in Ringer’s Lactate (mLuc-N), OVA mRNA (mOVA-NP) 
nanoparticles and non-transfected control (Control).  
b-c) C57Bl/6 mice were administered intranasally with 4g of Cy5-labeled green fluorescent 
protein mRNA (mGFP) encapsulated in nanoparticles. 30 minutes post-administration, nasal 
associated lymphoid tissue (NALT, b) and turbinate (c) were isolated, flushed 3 times with PBS 
and observed under IVIS (Kinetics, Caliper). Data is representative of 2 independent 
experiments.  
d) Two female C57Bl/6 mice were administered intranasally with 6g of Cy5-labeled mGFP 
encapsulated in nanoparticles. 4 hours post-administration, NALT from both mice were 
isolated and NALT cells were scraped off using a spatula. Cells were combined, blocked with 
CD16/32 (BioLegend), stained with CD11c-PE antibody (BioLegend), data acquired using flow 
cytometry (FACSCalibur) and analyzed using WinMDI 2.9 (freeware).  
 
 
135 
 
 
Supplementary Figure 9. Annexin V staining of Cy5-labeled GFP mRNA loaded leukocytes by 
electroporation. 
(A) Non-electroporated cells. 
 
(B) Cells electroporated without mRNA, 
 
(C) Cells electroporated with mRNA. Cells were stained with PE-labeled Annexin V and analyzed 
using flow cytometry. Plots are gated for leukocytes based on forward scatter. 
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Supplementary Figure 10. Analysis of phosphatidylserine (PS) expression in electroporated 
leukocytes. 
(A) Annexin V-PE staining of mRNA-loaded leukocytes (gated based on FSC) over 24 hours 
 
(B) Histogram plot of annexin V+ cells at 0 min (black) 2 hours (blue) and 24 hours (red). Control 
(shaded grey) represents pre-electroporated FSC-gated leukocytes. EP: electroporation 
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Supplementary Figure 11. Analysis of caspase 3 activation via luciferase activity mediated 
by release of aminoluciferin from caspase dependent DEVD cleavage.  
(tBOOH: tert-butylhydrogen peroxide, DEVD: Asp-Glu-Val-Asp ). 
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Supplementary Figure 12. Co-localization and uptake of whole blood cells loaded with Cy5-
labeled GFP mRNA by antigen-presenting cells.  
 
107 mRNA-loaded blood cells were co-cultured for 4 hours with 3x105 C57Bl/6 bone marrow-
derived dendritic cells (BMDC) in a 24-well plate. Unattached cells were aspirated and adherent 
cells were rinsed with PBS. Fluorescence microscope images of bone marrow-derived dendritic 
cells 8 hours(A) and 24 hours (B) post-incubation with mRNA-loaded blood cells is shown.  
(C) Flow cytometry quantification of Cy5+ dendritic cells or adherent splenocytes 24 hours post-
incubation with mRNA-loaded blood cells.  
 
Red: Cy5-RNA loaded blood cells. Blue: Hoechst stains for DC nuclei. 
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